PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23359127-0 2013 Anti-digoxin Fab variants generated by phage display. Digoxin 5-12 FA complementation group B Homo sapiens 13-16 22618329-4 2012 Patient was treated with 1,040 mg of digoxin-specific antibody Fab fragment with prompt resolution of arrhythmias and restoration of sinus rhythm. Digoxin 37-44 FA complementation group B Homo sapiens 63-66 23008361-5 2012 After a careful assessment by the cardiology consultant in charge, she received Digibind infusion for a chronic digitalis toxicity with the digoxin immune Fab dose based on the formula recommended in the product literature. Digoxin 140-147 FA complementation group B Homo sapiens 155-158 23250015-1 2012 Report of a case treated with digoxin-specific Fab antibody fragments]. Digoxin 30-37 FA complementation group B Homo sapiens 47-50 23559736-2 2012 Digoxin-specific antibody (Fab) fragments have become the mainstay of therapy for severe digoxin toxicity and have significantly helped in reducing mortality. Digoxin 0-7 FA complementation group B Homo sapiens 27-30 23559736-2 2012 Digoxin-specific antibody (Fab) fragments have become the mainstay of therapy for severe digoxin toxicity and have significantly helped in reducing mortality. Digoxin 89-96 FA complementation group B Homo sapiens 27-30 22824321-0 2012 First successful curative use of digoxin-specific Fab antibody fragments in a life-threatening coconut crab (Birgus latro L.) poisoning. Digoxin 33-40 FA complementation group B Homo sapiens 50-53 22824321-1 2012 We wish to report the first curative use of digoxin-specific Fab antibody fragments in a coconut crab Birgus latro L. poisoning in New Caledonia. Digoxin 44-51 FA complementation group B Homo sapiens 61-64 22824321-2 2012 The female patient, aged sixty-three with a previous history of cardiovascular and metabolic dysfunctions, showed marked first-degree atrio-ventricular block and several atrial pauses, and was given 760 mg of digoxin-specific Fab antibody fragments. Digoxin 209-216 FA complementation group B Homo sapiens 226-229 22824321-6 2012 The consumption of coconut crab in New Caledonia should be avoided even though the first of the two cases reported suggests that digoxin-specific Fab antibody fragments can be effective in the treatment of life-threatening poisoning caused by the ingestion of this crustacean. Digoxin 129-136 FA complementation group B Homo sapiens 146-149 20438743-6 2010 Digoxin specific Fab fragments are an effective treatment of acute intoxication by either species. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 21262953-1 2011 A retrospective study of 147 consecutive cases of suicidal digoxin poisoning was undertaken in order to determine the severity and outcome of toxicity without use of digoxin-specific Fab fragments. Digoxin 166-173 FA complementation group B Homo sapiens 183-186 21068223-0 2010 Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study. Digoxin 25-32 FA complementation group B Homo sapiens 79-82 20232280-0 2010 Digoxin immune fab treatment for severe preeclampsia. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 26105409-2 2012 INTRODUCTION: A double blinded placebo controlled clinical trial of a commercial digoxin immune Fab fragment (DIF) in preeclamptic (PE) women provided some benefit to treated subjects (1). Digoxin 81-88 FA complementation group B Homo sapiens 96-99 21068223-0 2010 Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study. Digoxin 64-71 FA complementation group B Homo sapiens 79-82 21068223-2 2010 In 1986, the US Food and Drug Administration (FDA) approved a digoxin immune Fab for the treatment of such patients. Digoxin 62-69 FA complementation group B Homo sapiens 77-80 21068223-3 2010 In 2001, the FDA approved a newer digoxin immune Fab, a digoxin-specific antibody (DSAb) known as DigiFab (Protherics Inc, Brentwood, Tennessee), though minimal literature exists on the clinical effects of this DSAb. Digoxin 34-41 FA complementation group B Homo sapiens 49-52 19875723-0 2010 Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Digoxin 15-22 FA complementation group B Homo sapiens 81-84 19875723-0 2010 Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Digoxin 58-65 FA complementation group B Homo sapiens 81-84 18824911-0 2008 Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 21686394-7 2009 A digoxin-specific Fab fragment was administered to this young woman 4 h subsequent to her admission. Digoxin 2-9 FA complementation group B Homo sapiens 19-22 21686562-4 2009 Paramedics were called and the patient was brought to the emergency room where he was confirmed to have digitalis toxicity and was quickly treated with digoxin-specific Fab antibody fragments. Digoxin 152-159 FA complementation group B Homo sapiens 169-172 20136482-2 2010 Because of renal insufficiency, cardiogenic shock, and high serum digoxin levels, the patient received continuous venovenous hemofiltration (CVVH) and digoxin-specific Fab fragments. Digoxin 151-158 FA complementation group B Homo sapiens 168-171 20136482-3 2010 Digoxin and the digoxin-specific Fab fragments are normally cleared by the kidneys. Digoxin 16-23 FA complementation group B Homo sapiens 33-36 19148110-0 2009 The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. Digoxin 39-46 FA complementation group B Homo sapiens 55-58 19148110-2 2009 This hypothesis is supported by two cases of preeclampsia in which administration of digoxin immune Fab (DIF) reduced mean arterial pressure (MAP). Digoxin 85-92 FA complementation group B Homo sapiens 100-103 16555861-3 2006 In addition, digoxin toxicity, once commonly fatal, can now be quickly and effectively treated by the emergency administration of antidigoxin Fab fragments. Digoxin 13-20 FA complementation group B Homo sapiens 142-145 18555269-5 2008 Consistent with previous results, both Fab preparations bound digoxin with the same affinities and capacities. Digoxin 62-69 FA complementation group B Homo sapiens 39-42 18072135-5 2006 We searched cases from 1982 to 2003, so that supportive care was similar and digoxin-specific Fab was available. Digoxin 77-84 FA complementation group B Homo sapiens 94-97 18072135-8 2006 Clinical data was collected, including information about treatment with digoxin-specific Fab and treatment outcome. Digoxin 72-79 FA complementation group B Homo sapiens 89-92 18940174-1 2008 In the case of severe digoxin intoxication, an antidote digoxin immune Fab (Digibind) is available. Digoxin 22-29 FA complementation group B Homo sapiens 71-74 18940174-1 2008 In the case of severe digoxin intoxication, an antidote digoxin immune Fab (Digibind) is available. Digoxin 56-63 FA complementation group B Homo sapiens 71-74 18940174-5 2008 A case involving Fab therapy of a digoxin-overdosed patient is reported. Digoxin 34-41 FA complementation group B Homo sapiens 17-20 16720112-0 2007 Characterisation of an industrial affinity process used in the manufacturing of digoxin-specific polyclonal Fab fragments. Digoxin 80-87 FA complementation group B Homo sapiens 108-111 16720112-1 2007 This paper describes the effect of several variables on the affinity process for the production of the FDA approved biotherapeutic product Digoxin Immune Fab (Ovine) (DigiFab, Protherics Inc., TN, USA). Digoxin 139-146 FA complementation group B Homo sapiens 154-157 16555861-4 2006 Indeed, it may be possible to expand the use of Fab fragments to select patients with non-life-threatening digoxin toxicity, in order to save costs and improve patient comfort. Digoxin 107-114 FA complementation group B Homo sapiens 48-51 17288498-6 2006 Exogenous compounds that interfere with digoxin assays are various drugs such as spironolactone, potassium canrenoate as well as Digibind (Fab fragment of antidigoxin antibody), which is used in treating life-threatening digoxin overdose. Digoxin 40-47 FA complementation group B Homo sapiens 139-142 17288498-6 2006 Exogenous compounds that interfere with digoxin assays are various drugs such as spironolactone, potassium canrenoate as well as Digibind (Fab fragment of antidigoxin antibody), which is used in treating life-threatening digoxin overdose. Digoxin 159-166 FA complementation group B Homo sapiens 139-142 15921882-3 2005 The patient was empirically treated in the prehospital phase with a single dose of digoxin-specific Fab antibody fragments (Digidot). Digoxin 83-90 FA complementation group B Homo sapiens 100-103 16382383-0 2005 Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child: case report and review of literature. Digoxin 72-79 FA complementation group B Homo sapiens 89-92 16382383-3 2005 The patient was then treated with two intravenous doses of 190 mg of digoxin-specific Fab antibody fragments (Digibind). Digoxin 69-76 FA complementation group B Homo sapiens 86-89 14982968-6 2004 Digoxin-specific Fab had the ability to interact to some extent with all of the cardenolides and bufodienolides tested. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 14982968-0 2004 Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. Digoxin 49-56 FA complementation group B Homo sapiens 66-69 14982968-1 2004 Digoxin-specific Fab (Digibind) is a mixture of antidigoxin Fab fragments prepared from sheep sera and is used as a treatment for digoxin poisoning. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 14982968-1 2004 Digoxin-specific Fab (Digibind) is a mixture of antidigoxin Fab fragments prepared from sheep sera and is used as a treatment for digoxin poisoning. Digoxin 0-7 FA complementation group B Homo sapiens 60-63 14982968-1 2004 Digoxin-specific Fab (Digibind) is a mixture of antidigoxin Fab fragments prepared from sheep sera and is used as a treatment for digoxin poisoning. Digoxin 52-59 FA complementation group B Homo sapiens 17-20 14982968-2 2004 Digoxin-specific Fab has been shown to neutralize an endogenous Na+/K+ ATPase inhibitor (endogenous digoxin-like Na+/K+ ATPase regulatory factor; EDLF) in rats and humans and to lower blood pressure. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 14982968-4 2004 In this study, some structural characteristics of EDLF were inferred from the ability of digoxin-specific Fab to neutralize the Na+/K+ ATPase inhibitory activity of several known cardenolides and bufodienolides. Digoxin 89-96 FA complementation group B Homo sapiens 106-109 14982968-7 2004 However, digoxin-specific Fab was more than 20-fold more potent in neutralizing ouabain and bufalin than marinobufagenin. Digoxin 9-16 FA complementation group B Homo sapiens 26-29 14982968-8 2004 The antihypertensive effect of digoxin-specific Fab seen in preeclampsia and animal models of hypertension may therefore be due to a molecule identical to or structurally similar to ouabain or bufalin. Digoxin 31-38 FA complementation group B Homo sapiens 48-51 12639891-8 2003 Digoxin specific Fab fragment has been reported to be beneficial in the treatment of toad venom poisoning. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 15554746-1 2004 This review provides current information on the use of antigen-binding fragments (Fab) from cleaved antibodies to treat poisoning with digoxin and other potent, low formula mass poisons, such as colchicine and tricyclic antidepressants. Digoxin 135-142 FA complementation group B Homo sapiens 82-85 15554746-2 2004 Anti-digoxin Fab fragments have been used successfully for many years in the management of severe poisoning with digoxin, digitoxin, and a range of other structurally related compounds, including cardiotoxins from Nerium and Thevetia sp. Digoxin 5-12 FA complementation group B Homo sapiens 13-16 15554746-6 2004 Equimolar doses of anti-digoxin Fab fragments completely bind digoxin in vivo. Digoxin 24-31 FA complementation group B Homo sapiens 32-35 15554746-6 2004 Equimolar doses of anti-digoxin Fab fragments completely bind digoxin in vivo. Digoxin 62-69 FA complementation group B Homo sapiens 32-35 15554746-7 2004 The approximate dose of Fab fragments (mg) is 80 times the digoxin body burden (mg). Digoxin 59-66 FA complementation group B Homo sapiens 24-27 15554746-8 2004 If neither the dose ingested nor the plasma digoxin/digitoxin concentration is known, in an adult 380 mg of anti-digoxin Fab fragments should be given. Digoxin 113-120 FA complementation group B Homo sapiens 121-124 14983943-0 2004 Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Digoxin 23-30 FA complementation group B Homo sapiens 116-119 15862081-1 2004 Digitalis glycoside poisoning is an important clinical problem and the development of digoxin-specific antibody fragments (Fab) 30 years ago has changed clinical practice. Digoxin 86-93 FA complementation group B Homo sapiens 123-126 14711605-0 2003 [Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist]. Digoxin 5-12 FA complementation group B Homo sapiens 13-16 14711605-1 2003 Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Digoxin 33-40 FA complementation group B Homo sapiens 41-44 14711605-1 2003 Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Digoxin 75-82 FA complementation group B Homo sapiens 41-44 14711605-8 2003 Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. Digoxin 6-13 FA complementation group B Homo sapiens 118-121 14711605-8 2003 Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. Digoxin 110-117 FA complementation group B Homo sapiens 118-121 12639891-9 2003 This report alerts physicians to the need to be aware of a new community toxic exposure, as prompt treatment with digoxin specific Fab fragment may be life saving. Digoxin 114-121 FA complementation group B Homo sapiens 131-134 12605208-7 2003 After empiric therapy with 10 vials of digoxin-specific Fab (Digibind), her symptoms resolved, and she reverted to a sinus rhythm at a rate of 68 beats/min. Digoxin 39-46 FA complementation group B Homo sapiens 56-59 12605208-12 2003 An empiric dose of 10 vials of digoxin-specific Fab might be beneficial in patients poisoned with an unknown cardioactive steroid. Digoxin 31-38 FA complementation group B Homo sapiens 48-51 10911530-1 2000 BACKGROUND: Despite the great progress which has been made in the treatment of acute digitalis intoxication by digoxin-immune Fab, it still remains a severe complication of cardiotonic therapy. Digoxin 111-118 FA complementation group B Homo sapiens 126-129 11468950-5 2001 Only 9% of the hospitals stocked an adequate supply of digoxin immune Fab antibody fragments, a life-saving antidote for patients with severe digoxin toxicity, whereas most of the hospitals stocked sufficient supplies of ipecac syrup (88%) and flumazenil (92%), arguably the least crucial antidotes in the survey. Digoxin 55-62 FA complementation group B Homo sapiens 70-73 11174238-7 2001 Similar phenomena of symptom recurrence have been observed with ovine, digoxin-specific Fab, and with Fab2 and IgG antivenoms from a variety of source animals as well. Digoxin 71-78 FA complementation group B Homo sapiens 88-91 11207409-6 2001 Management varies from temporary withdrawal of the medication to administration of digoxin-specific Fab fragments for life-threatening cardiovascular compromise. Digoxin 83-90 FA complementation group B Homo sapiens 100-103 11034267-10 2000 The ability of digoxinimmune Fab to bind to digoxin is not affected by the systemic disposition of the Fab product. Digoxin 15-22 FA complementation group B Homo sapiens 29-32 10873888-1 2000 Life-threatening digoxin toxicity may be effectively treated with digoxin-specific antibody fragments (Fab). Digoxin 17-24 FA complementation group B Homo sapiens 103-106 10873888-1 2000 Life-threatening digoxin toxicity may be effectively treated with digoxin-specific antibody fragments (Fab). Digoxin 66-73 FA complementation group B Homo sapiens 103-106 10873888-2 2000 However, in end-stage renal disease, the digoxin-Fab complexes persist in the circulation and dissociate, potentially resulting in rebounding free digoxin levels and the recurrence of symptomatic toxicity. Digoxin 41-48 FA complementation group B Homo sapiens 49-52 10873888-3 2000 To prevent this rebound phenomenon, plasma exchange (PE) has been implemented for the removal of the digoxin-Fab complexes in renal failure. Digoxin 101-108 FA complementation group B Homo sapiens 109-112 10873888-8 2000 The plasma ultrafiltrate digoxin concentration was 2.5-fold greater when PE was performed 2.5 hours versus 26 hours after Fab administration (19.9 versus 8.1 ng/mL). Digoxin 25-32 FA complementation group B Homo sapiens 122-125 10873888-11 2000 Although PE is efficacious for removing digoxin-Fab complexes, thus preventing rebound digoxin toxicity, it is not efficacious for improving total digoxin clearance because of the large apparent volume of distribution of digoxin (5 to 8 L/kg). Digoxin 40-47 FA complementation group B Homo sapiens 48-51 12554051-0 2003 Late rebound digoxin toxicity after digoxin-specific antibody Fab fragments therapy in anuric patient. Digoxin 13-20 FA complementation group B Homo sapiens 62-65 12554051-0 2003 Late rebound digoxin toxicity after digoxin-specific antibody Fab fragments therapy in anuric patient. Digoxin 36-43 FA complementation group B Homo sapiens 62-65 12870880-5 2003 The patient received digoxin-specific Fab fragments and hemodialysis as definitive therapeutic modalities. Digoxin 21-28 FA complementation group B Homo sapiens 38-41 12023714-4 2002 Experience from premarketing trials of this product and in the administration of other types of Fab, such as in digoxin poisoning, has demonstrated these fragments to be safe and effective, with a low incidence of sequella; however, allergic reactions can occur when any animal-protein derivatives are administered to human subjects. Digoxin 112-119 FA complementation group B Homo sapiens 96-99 12117293-0 2002 Digoxin poisoning and anuric acute renal failure: efficiency of the treatment associating digoxin-specific antibodies (Fab) and plasma exchanges. Digoxin 0-7 FA complementation group B Homo sapiens 119-122 12117293-0 2002 Digoxin poisoning and anuric acute renal failure: efficiency of the treatment associating digoxin-specific antibodies (Fab) and plasma exchanges. Digoxin 90-97 FA complementation group B Homo sapiens 119-122 12117293-1 2002 Digoxin-specific antibodies (Fab) are currently the treatment of choice for digoxin intoxication. Digoxin 0-7 FA complementation group B Homo sapiens 29-32 12117293-1 2002 Digoxin-specific antibodies (Fab) are currently the treatment of choice for digoxin intoxication. Digoxin 76-83 FA complementation group B Homo sapiens 29-32 12117293-2 2002 These fragments bind to digoxin, leading to Fab-digoxin complexes, and promote the release of receptor-bound digoxin. Digoxin 24-31 FA complementation group B Homo sapiens 44-47 12117293-2 2002 These fragments bind to digoxin, leading to Fab-digoxin complexes, and promote the release of receptor-bound digoxin. Digoxin 48-55 FA complementation group B Homo sapiens 44-47 12117293-2 2002 These fragments bind to digoxin, leading to Fab-digoxin complexes, and promote the release of receptor-bound digoxin. Digoxin 48-55 FA complementation group B Homo sapiens 44-47 12117293-6 2002 We report the case of an anuric patient with digoxin intoxication, treated with a Fab injection, followed by a plasma exchange 16 hours later, a second Fab injection was given followed by two plasma exchanges, 38 and 86 hours later. Digoxin 45-52 FA complementation group B Homo sapiens 82-85 12117293-8 2002 The association of Fab and plasma exchanges could be proposed in the case of digoxin intoxication in the anuric patient. Digoxin 77-84 FA complementation group B Homo sapiens 19-22 11858929-0 2002 Late rebound digoxin toxicity after digoxin-specific antibody Fab fragments therapy in anuric patient. Digoxin 13-20 FA complementation group B Homo sapiens 62-65 11858929-0 2002 Late rebound digoxin toxicity after digoxin-specific antibody Fab fragments therapy in anuric patient. Digoxin 36-43 FA complementation group B Homo sapiens 62-65 11060305-3 2001 When a mutant Fab that binds 16-substituted analogs preferentially was used as a parent sequence, clones were obtained with affinities for digoxin increased 2-4-fold, by panning on digoxin-BSA yet retaining the specificity shift. Digoxin 139-146 FA complementation group B Homo sapiens 14-17 11060305-3 2001 When a mutant Fab that binds 16-substituted analogs preferentially was used as a parent sequence, clones were obtained with affinities for digoxin increased 2-4-fold, by panning on digoxin-BSA yet retaining the specificity shift. Digoxin 181-188 FA complementation group B Homo sapiens 14-17 11060305-5 2001 The residues at both position H95 (serine) and position H100 (tryptophan) contact hapten in the crystal structure of the Fab 26-10-digoxin complex. Digoxin 131-138 FA complementation group B Homo sapiens 121-124 11034267-1 2000 The in vivo digoxin binding affinity and normal pharmacokinetic values of digoxin-immune Fab are unknown. Digoxin 74-81 FA complementation group B Homo sapiens 89-92 11034267-2 2000 Healthy subjects (n = 16) were randomized to one of the two digoxin-immune Fab products, DigiTAb or Digibind, to compare the in vivo digoxin binding affinity and pharmacokinetic disposition. Digoxin 60-67 FA complementation group B Homo sapiens 75-78 11034267-4 2000 Both Fab products reduced free digoxin serum concentrations to below assay detection with equal ability. Digoxin 31-38 FA complementation group B Homo sapiens 5-8 10438974-1 1999 Fab preparations of sheep polyclonal anti-digoxin Abs have proven useful for reversal of the toxic effects of digoxin overdoses in patients. Digoxin 42-49 FA complementation group B Homo sapiens 0-3 11150387-0 2000 Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity. Digoxin 84-91 FA complementation group B Homo sapiens 38-41 11150387-1 2000 BACKGROUND: Studies indicate that digoxin toxicity often results in lengthy hospitalizations and considerable costs, both of which may be decreased through the routine use of digoxin immune Fab (FAB). Digoxin 34-41 FA complementation group B Homo sapiens 190-193 11150387-1 2000 BACKGROUND: Studies indicate that digoxin toxicity often results in lengthy hospitalizations and considerable costs, both of which may be decreased through the routine use of digoxin immune Fab (FAB). Digoxin 34-41 FA complementation group B Homo sapiens 195-198 11150387-1 2000 BACKGROUND: Studies indicate that digoxin toxicity often results in lengthy hospitalizations and considerable costs, both of which may be decreased through the routine use of digoxin immune Fab (FAB). Digoxin 175-182 FA complementation group B Homo sapiens 190-193 11150387-1 2000 BACKGROUND: Studies indicate that digoxin toxicity often results in lengthy hospitalizations and considerable costs, both of which may be decreased through the routine use of digoxin immune Fab (FAB). Digoxin 175-182 FA complementation group B Homo sapiens 195-198 11150387-10 2000 CONCLUSIONS: The abbreviated LOS associated with the use of FAB in patients with non-life-threatening digoxin toxicity may translate into lower treatment costs in many clinical scenarios, making it a cost-saving alternative to standard therapy in patients with high SDC and renal dysfunction. Digoxin 102-109 FA complementation group B Homo sapiens 60-63 10712977-2 2000 In our environment, the use of Fab antibodies for digoxin intoxication is often difficult due to the low availability of this drug in most centers. Digoxin 50-57 FA complementation group B Homo sapiens 31-34 10647847-2 2000 In the present study, we have utilized a panel of mutant antibodies and Fab fragments, previously characterized for their importance in the binding affinity of digoxin:26-10, to probe the molecular basis of pressure sensitivity in this complex, as measured by fluorescence polarization spectroscopy. Digoxin 160-167 FA complementation group B Homo sapiens 72-75 10438974-1 1999 Fab preparations of sheep polyclonal anti-digoxin Abs have proven useful for reversal of the toxic effects of digoxin overdoses in patients. Digoxin 110-117 FA complementation group B Homo sapiens 0-3 10404740-1 1999 Measurement of unbound digoxin in presence of Fab fragments may be useful in management of overdoses. Digoxin 23-30 FA complementation group B Homo sapiens 46-49 9429088-6 1997 Digoxin specific antibody fragments (Fab) were not readily available and their use was probably inappropriate as they are normally renally eliminated. Digoxin 0-7 FA complementation group B Homo sapiens 37-40 10335044-3 1998 Ventricular arrhythmias and severe conduction disturbances are the most threatening sings may need the use of antiarrhythmic agents, temporally endocardial stimulation or digoxin specific antibody Fab fragments. Digoxin 171-178 FA complementation group B Homo sapiens 197-200 10217348-1 1999 Digoxin fab antibody (Digibind; Burroughs Wellcome, Research Triangle Park, NC, USA) is used in the treatment of digoxin overdose. Digoxin 0-7 FA complementation group B Homo sapiens 8-11 10217348-1 1999 Digoxin fab antibody (Digibind; Burroughs Wellcome, Research Triangle Park, NC, USA) is used in the treatment of digoxin overdose. Digoxin 113-120 FA complementation group B Homo sapiens 8-11 9617829-3 1998 The excess of Fab-fragments was then separated from the digoxin bound Fab-fragments by passing the sample through a column with immobilised digoxin. Digoxin 56-63 FA complementation group B Homo sapiens 70-73 9617829-7 1998 The highest sensitivity and lowest limit of detection (LOD) was obtained with the Fab-POD system with LODs for digoxin and digoxigenin in the off- and on-line configurations of 0.025 and 0.01 nM, respectively. Digoxin 111-118 FA complementation group B Homo sapiens 82-85 9499730-3 1998 All patients received specific digoxin Fab-fragment intravenously. Digoxin 31-38 FA complementation group B Homo sapiens 39-42 9278197-0 1997 Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Digoxin 20-27 FA complementation group B Homo sapiens 37-40 9278197-1 1997 AIMS: To study the influence of age and renal function on digoxin-specific Fab (DS-Fab) pharmacokinetics. Digoxin 58-65 FA complementation group B Homo sapiens 75-78 9278197-1 1997 AIMS: To study the influence of age and renal function on digoxin-specific Fab (DS-Fab) pharmacokinetics. Digoxin 58-65 FA complementation group B Homo sapiens 83-86 8915235-0 1996 Treatment of toad venom poisoning with digoxin-specific Fab fragments. Digoxin 39-46 FA complementation group B Homo sapiens 56-59 9280884-5 1997 Considering the probable long elimination period of digitalis and the potentially life-threatening situation the patients were given digoxin-specific antibody (Fab) fragments with potassium replacement therapy. Digoxin 133-140 FA complementation group B Homo sapiens 160-163 9108648-2 1997 Digoxin FAB antibody (Digibind) is also known to affect digoxin results by FPIA assay. Digoxin 0-7 FA complementation group B Homo sapiens 8-11 9108648-2 1997 Digoxin FAB antibody (Digibind) is also known to affect digoxin results by FPIA assay. Digoxin 56-63 FA complementation group B Homo sapiens 8-11 9002573-5 1997 Even fewer hospital pharmacies stocked specific antidotes (eg, Crotalid anti-venin, digoxin-specific Fab antibodies, pyridoxine) in an adequate quantity to treat one poisoned adult. Digoxin 84-91 FA complementation group B Homo sapiens 101-104 9010641-12 1997 Some antidotes, such as digoxin-specific antigen binding fragments (digoxin immune Fab), are very expensive, and both the risk: benefit ratio and the associated cost should be considered before the antidote is administered. Digoxin 24-31 FA complementation group B Homo sapiens 83-86 9111705-6 1997 Digoxin-specific Fab therapy may result in dramatic recovery from digoxin intoxication, but it must be administered early and in a an adequate dosage if reductions in mortality are to be achieved. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 9111705-6 1997 Digoxin-specific Fab therapy may result in dramatic recovery from digoxin intoxication, but it must be administered early and in a an adequate dosage if reductions in mortality are to be achieved. Digoxin 66-73 FA complementation group B Homo sapiens 17-20 8915235-6 1996 To our knowledge, this is the first reported use of digoxin Fab fragments to treat toad venom poisoning. Digoxin 52-59 FA complementation group B Homo sapiens 60-63 8839532-2 1996 We report a case in which hyperkalemia, bradycardia, and hypotension were unresponsive to standard therapy but appeared to respond to digoxin-specific antibodies (Fab). Digoxin 134-141 FA complementation group B Homo sapiens 163-166 8658517-0 1996 Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Digoxin 65-72 FA complementation group B Homo sapiens 82-85 8658517-1 1996 Digoxin-specific Fab are recognized to be effective in the treatment of acute cardiac glycoside poisoning but no pharmacokinetic studies have been performed in human volunteers. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 8658517-3 1996 Plasma disposition of digoxin-specific Fab was studied at a 20 mg/kg i.v. Digoxin 22-29 FA complementation group B Homo sapiens 39-42 7739045-1 1995 We determined the sequence, specificity for structurally related cardenolides, and three-dimensional structure of the anti-digoxin antibody 40-50 Fab in complex with ouabain. Digoxin 123-130 FA complementation group B Homo sapiens 146-149 8716303-0 1996 Reversing life-threatening cardiac glycoside intoxication with digoxin immune Fab. Digoxin 63-70 FA complementation group B Homo sapiens 78-81 8733598-0 1996 The affinity of binding of digoxin to ovine anti-digoxin Fab (DIGIBIND) preparations. Digoxin 27-34 FA complementation group B Homo sapiens 57-60 8733598-1 1996 A fundamental study was performed to assess the binding characteristics of an ovine anti-digoxin-Fab preparations, DIGIBIND, for digoxin, using equilibrium dialysis. Digoxin 89-96 FA complementation group B Homo sapiens 97-100 7664510-0 1995 Rapid reversal of digitalis delirium using digoxin immune Fab therapy. Digoxin 43-50 FA complementation group B Homo sapiens 58-61 7664510-3 1995 Digoxin immune Fab therapy was begun because of the fulminant psychiatric manifestations of this toxic state and the clear danger of self-inflicted physical harm. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 7656506-0 1995 Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Digoxin 27-34 FA complementation group B Homo sapiens 44-47 7656506-1 1995 Digoxin intoxication occurs frequently and may require treatment with digoxin-specific Fab therapy. Digoxin 0-7 FA complementation group B Homo sapiens 87-90 7656506-1 1995 Digoxin intoxication occurs frequently and may require treatment with digoxin-specific Fab therapy. Digoxin 70-77 FA complementation group B Homo sapiens 87-90 7656506-4 1995 Digoxin-specific Fab is eliminated via renal and nonrenal routes, having a volume of distribution slightly exceeding extracellular volume (0.40 L/kg) and an elimination half-life of 16 to 20 hours. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 7656506-6 1995 Systemic clearance of digoxin-specific Fab is approximately 0.32 ml/min/kg in digoxin-toxic patients with preserved renal function. Digoxin 22-29 FA complementation group B Homo sapiens 39-42 7656506-6 1995 Systemic clearance of digoxin-specific Fab is approximately 0.32 ml/min/kg in digoxin-toxic patients with preserved renal function. Digoxin 78-85 FA complementation group B Homo sapiens 39-42 7656506-9 1995 More important is the effect of Fab on the disposition of digoxin. Digoxin 58-65 FA complementation group B Homo sapiens 32-35 7656506-10 1995 Because digoxin-specific Fab has a stronger digoxin-binding affinity than do biological membranes, it can sequester tissue-bound and intracellular digoxin into the extracellular spaces. Digoxin 8-15 FA complementation group B Homo sapiens 25-28 7656506-10 1995 Because digoxin-specific Fab has a stronger digoxin-binding affinity than do biological membranes, it can sequester tissue-bound and intracellular digoxin into the extracellular spaces. Digoxin 44-51 FA complementation group B Homo sapiens 25-28 7656506-10 1995 Because digoxin-specific Fab has a stronger digoxin-binding affinity than do biological membranes, it can sequester tissue-bound and intracellular digoxin into the extracellular spaces. Digoxin 44-51 FA complementation group B Homo sapiens 25-28 7656506-12 1995 Since the majority of digoxin is bound by Fab, it cannot interact with its biological receptor and thus reverses digoxin toxicity. Digoxin 22-29 FA complementation group B Homo sapiens 42-45 7656506-12 1995 Since the majority of digoxin is bound by Fab, it cannot interact with its biological receptor and thus reverses digoxin toxicity. Digoxin 113-120 FA complementation group B Homo sapiens 42-45 7656506-13 1995 The pharmacokinetic fate of total digoxin after administration of digoxin-specific Fab follows that of Fab. Digoxin 34-41 FA complementation group B Homo sapiens 83-86 7656506-13 1995 The pharmacokinetic fate of total digoxin after administration of digoxin-specific Fab follows that of Fab. Digoxin 34-41 FA complementation group B Homo sapiens 103-106 7656506-13 1995 The pharmacokinetic fate of total digoxin after administration of digoxin-specific Fab follows that of Fab. Digoxin 66-73 FA complementation group B Homo sapiens 83-86 7656506-13 1995 The pharmacokinetic fate of total digoxin after administration of digoxin-specific Fab follows that of Fab. Digoxin 66-73 FA complementation group B Homo sapiens 103-106 7656506-15 1995 Free digoxin concentrations fall rapidly after Fab administration and then rebound upwards within 12 to 24 hours. Digoxin 5-12 FA complementation group B Homo sapiens 47-50 7656506-17 1995 Rebound in free digoxin concentrations occurs during the initial phase of the biexponential decline of the serum concentration-time profile for digoxin-specific Fab, suggesting that distribution from the vascular spaces is the likely cause. Digoxin 16-23 FA complementation group B Homo sapiens 161-164 7656506-17 1995 Rebound in free digoxin concentrations occurs during the initial phase of the biexponential decline of the serum concentration-time profile for digoxin-specific Fab, suggesting that distribution from the vascular spaces is the likely cause. Digoxin 144-151 FA complementation group B Homo sapiens 161-164 7656506-19 1995 During this time period it is evident that Fab retains it capability of binding digoxin while it resides in plasma. Digoxin 80-87 FA complementation group B Homo sapiens 43-46 8574808-4 1995 Anti-ouabain rabbit antiserum and anti-digoxin Fab fragments induced a significantly greater percentage change in 86Rb uptake in the erythrocytes than the two control sera (ANOVA followed by multiple comparison by the Games-Howell test). Digoxin 39-46 FA complementation group B Homo sapiens 47-50 7725380-10 1995 A case study of a patient treated with anti-digoxin Fab fragments (Digibind) also was included for analysis by each method. Digoxin 44-51 FA complementation group B Homo sapiens 52-55 8587010-0 1995 Problems in determining levels of free digoxin in patients treated with digoxin immune FAb. Digoxin 39-46 FA complementation group B Homo sapiens 87-90 8587010-0 1995 Problems in determining levels of free digoxin in patients treated with digoxin immune FAb. Digoxin 72-79 FA complementation group B Homo sapiens 87-90 8587010-1 1995 Determination of free digoxin levels in patients treated with digoxin immune FAb has long been a problematic area in clinical laboratory testing. Digoxin 22-29 FA complementation group B Homo sapiens 77-80 8587010-1 1995 Determination of free digoxin levels in patients treated with digoxin immune FAb has long been a problematic area in clinical laboratory testing. Digoxin 62-69 FA complementation group B Homo sapiens 77-80 8587010-3 1995 The 1995 Physicians" Desk Reference continues to state that digoxin immune FAb will interfere with digitalis immunoassay measurements. Digoxin 60-67 FA complementation group B Homo sapiens 75-78 8587010-11 1995 The Stratus digoxin assay may be an accurate and objective way of measuring free digoxin levels in patients on digoxin immune FAb. Digoxin 12-19 FA complementation group B Homo sapiens 126-129 8587010-11 1995 The Stratus digoxin assay may be an accurate and objective way of measuring free digoxin levels in patients on digoxin immune FAb. Digoxin 81-88 FA complementation group B Homo sapiens 126-129 8587010-11 1995 The Stratus digoxin assay may be an accurate and objective way of measuring free digoxin levels in patients on digoxin immune FAb. Digoxin 81-88 FA complementation group B Homo sapiens 126-129 8650409-0 1996 [Severe digoxin intoxication in a 15-year-old girl treated with Fab antidigoxin]. Digoxin 8-15 FA complementation group B Homo sapiens 64-67 15299362-1 1994 The Fab fragments of several monoclonal antibodies that bind digoxin and other cardiac glycosides have been screened for crystallization conditions. Digoxin 61-68 FA complementation group B Homo sapiens 4-7 7739045-12 1995 Comparison of the crystal structures of 40-50 complexed with ouabain and the previously determined 26-10 anti-digoxin Fab complexed with digoxin, demonstrates that the antibodies bind these structurally related haptens in different orientations, consistent with their different fine specificities. Digoxin 110-117 FA complementation group B Homo sapiens 118-121 7739045-12 1995 Comparison of the crystal structures of 40-50 complexed with ouabain and the previously determined 26-10 anti-digoxin Fab complexed with digoxin, demonstrates that the antibodies bind these structurally related haptens in different orientations, consistent with their different fine specificities. Digoxin 137-144 FA complementation group B Homo sapiens 118-121 7846755-3 1994 In patients who have renal failure and who have been treated with digoxin-Fab, the elimination of the digoxin-Fab complex is significantly delayed, and there is a risk of dissociation of the complex with rebound of free digoxin and recurrence of toxicity. Digoxin 66-73 FA complementation group B Homo sapiens 74-77 7846755-3 1994 In patients who have renal failure and who have been treated with digoxin-Fab, the elimination of the digoxin-Fab complex is significantly delayed, and there is a risk of dissociation of the complex with rebound of free digoxin and recurrence of toxicity. Digoxin 66-73 FA complementation group B Homo sapiens 110-113 7846755-5 1994 A 3-day-old newborn with digoxin overdose and acute renal failure was treated with digoxin immune Fab and peritoneal dialysis. Digoxin 25-32 FA complementation group B Homo sapiens 98-101 7979107-0 1994 Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. Digoxin 0-7 FA complementation group B Homo sapiens 114-117 1523016-5 1992 Finally, several new and old antidotes are reviewed, namely naloxone, glucagon, bicarbonate, dimercaptosuccinic acid, digoxin-specific fab fragments, and flumazenil. Digoxin 118-125 FA complementation group B Homo sapiens 135-138 8107112-18 1994 The backbone atom and all heavy atom r.m.s.d.s between the mean energy-minimized DIANA structure and the X-ray derived coordinates of the VL domain within the Fab/digoxin complex are 1.05 A and 1.56 A, respectively. Digoxin 163-170 FA complementation group B Homo sapiens 159-162 8115274-1 1994 A 20-month-old girl with massive digitoxin intoxication (initial digitoxin serum level: 629 ng/ml) was successfully treated with digoxin-specific antibody fragments (Fab). Digoxin 129-136 FA complementation group B Homo sapiens 166-169 8288449-3 1993 Despite increased telemetry and development of a sensitive radioimmune assay of serum digoxin levels and the availability of digoxin immune Fab fragments (Digibind) to treat digitalis-induced life-threatening dysrhythmias, toxicity remains a serious and common problem. Digoxin 125-132 FA complementation group B Homo sapiens 140-143 8234291-0 1993 26-10 Fab-digoxin complex: affinity and specificity due to surface complementarity. Digoxin 10-17 FA complementation group B Homo sapiens 6-9 8321833-1 1993 Anti-sheep Fab fragment antisera were produced in rabbits using sheep digoxin-specific Fab fragments (Digidot) as immunogen. Digoxin 70-77 FA complementation group B Homo sapiens 87-90 8321833-7 1993 RIA was applied to the pharmacokinetic study of sheep digoxin-specific Fab fragments in one patient acutely intoxicated by digitoxin and treated with Digidot. Digoxin 54-61 FA complementation group B Homo sapiens 71-74 7508020-4 1993 The inhibitory activity of this factor on 86Rb uptake could be neutralized by antidigoxin antibodies (Fab fragments) and provided, for the first time, direct evidence of an association between digoxin-like immunoreactivity and biological digitalis-like activity. Digoxin 82-89 FA complementation group B Homo sapiens 102-105 8207153-0 1994 Recurrent digoxin overdose and treatment with digoxin-specific Fab antibody fragments. Digoxin 46-53 FA complementation group B Homo sapiens 63-66 8207153-2 1994 The patient received digoxin-specific Fab antibody fragments on each presentation without adverse effects. Digoxin 21-28 FA complementation group B Homo sapiens 38-41 8207162-0 1994 Pitfalls in the administration of digoxin-specific Fab fragments. Digoxin 34-41 FA complementation group B Homo sapiens 51-54 8273992-0 1994 Digoxin immune Fab therapy for digoxin toxicity. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 8273992-0 1994 Digoxin immune Fab therapy for digoxin toxicity. Digoxin 31-38 FA complementation group B Homo sapiens 15-18 7691815-4 1993 Consistent with these data, the 26-10 Fab-digoxin x-ray crystal structure (Jeffrey, P. D., Strong, R. K., Sieker, L. C., Chang, C. Y., Campbell, R. L., Petsko, G. A., Haber, E., Margolies, M. N., and Sheriff, S. (1993) Proc. Digoxin 42-49 FA complementation group B Homo sapiens 38-41 8222481-0 1993 Disposition of digoxin immune Fab in patients with kidney failure. Digoxin 15-22 FA complementation group B Homo sapiens 30-33 8222481-1 1993 Digoxin and digoxin immune Fab, its antidote, are eliminated renally. Digoxin 12-19 FA complementation group B Homo sapiens 27-30 8222481-3 1993 Therefore, the disposition of Fab and its relationship to total and free digoxin were studied in five digoxin-toxic patients with end-stage renal disease (n = 4) or severe renal dysfunction (n = 1) with a mean (+/- SD) serum creatinine of 5.9 +/- 1.2 mg/dl (four patients were receiving long-term hemodialysis). Digoxin 73-80 FA complementation group B Homo sapiens 30-33 8403971-0 1993 Reinstitution of digoxin after digoxin Fab antibody therapy in a hemodialyzed patient. Digoxin 17-24 FA complementation group B Homo sapiens 39-42 8222341-7 1993 Infusion into the fetal circulation of Fab fragments of sheep antibodies to digoxin caused vasodilatation, indicated by a fall in perfusion pressure. Digoxin 76-83 FA complementation group B Homo sapiens 39-42 8328735-1 1993 OBJECTIVE: To characterize the disposition of total and free serum digoxin following the administration of digoxin Fab antibody in patients with varying degrees of renal function. Digoxin 67-74 FA complementation group B Homo sapiens 115-118 8328735-8 1993 After treatment with Fab, total digoxin increased rapidly to a mean (+/- SD) maximum of 51.8 +/- 22.7 nmol/mL and decreased to 7.2 +/- 4.7 nmol/mL at the last measurement. Digoxin 32-39 FA complementation group B Homo sapiens 21-24 8328735-11 1993 Free digoxin levels decreased rapidly following Fab therapy, to a mean nadir of 0.6 +/- 1.1 nmol/mL, but rebounded to a mean maximum free digoxin concentration of 1.7 +/- 1.3 nmol/mL in 77 +/- 46 hours. Digoxin 5-12 FA complementation group B Homo sapiens 48-51 8328735-13 1993 CONCLUSION: Elimination of digoxin following Fab therapy is prolonged in digoxin-toxic patients with renal dysfunction. Digoxin 27-34 FA complementation group B Homo sapiens 45-48 8328735-13 1993 CONCLUSION: Elimination of digoxin following Fab therapy is prolonged in digoxin-toxic patients with renal dysfunction. Digoxin 73-80 FA complementation group B Homo sapiens 45-48 8328735-15 1993 Monitoring free digoxin following the administration of Fab may be of value in selected patients to guide additional Fab dosing, confirm possible rebound toxicity, or guide the reinitiation of digoxin therapy. Digoxin 16-23 FA complementation group B Homo sapiens 56-59 8328735-15 1993 Monitoring free digoxin following the administration of Fab may be of value in selected patients to guide additional Fab dosing, confirm possible rebound toxicity, or guide the reinitiation of digoxin therapy. Digoxin 16-23 FA complementation group B Homo sapiens 117-120 8456098-8 1993 The degree of local flexibility indicated by the NMR measurements is compared to crystallographic B-factors derived from X-ray analyses of the native Fab and the Fab/digoxin complex. Digoxin 166-173 FA complementation group B Homo sapiens 162-165 8443598-6 1993 The crystal structure of the 26-10 Fab complexed with digoxin (P.D.J., R.K. Strong, L.C. Digoxin 54-61 FA complementation group B Homo sapiens 35-38 1594015-0 1992 The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. Digoxin 11-18 FA complementation group B Homo sapiens 28-31 1594015-1 1992 BACKGROUND: Because life-threatening digitalis intoxication is unusual in children, treatment with digoxin-specific-antibody Fab fragments (Fab) has rarely been reported. Digoxin 99-106 FA complementation group B Homo sapiens 125-128 1594015-1 1992 BACKGROUND: Because life-threatening digitalis intoxication is unusual in children, treatment with digoxin-specific-antibody Fab fragments (Fab) has rarely been reported. Digoxin 99-106 FA complementation group B Homo sapiens 140-143 1594015-13 1992 CONCLUSIONS: We recommend that Fab be used in the treatment of digitalis poisoning in infants and young children who have ingested greater than or equal to 0.3 mg of digoxin per kilogram, who have underlying heart disease, or who have a serum digoxin concentration of greater than or equal to 6.4 nmol per liter (greater than or equal to 5.0 ng per milliliter) in the elimination phase; and who also have a life-threatening arrhythmia, hemodynamic instability, hyperkalemia, or rapidly progressive toxicity. Digoxin 166-173 FA complementation group B Homo sapiens 31-34 1594015-13 1992 CONCLUSIONS: We recommend that Fab be used in the treatment of digitalis poisoning in infants and young children who have ingested greater than or equal to 0.3 mg of digoxin per kilogram, who have underlying heart disease, or who have a serum digoxin concentration of greater than or equal to 6.4 nmol per liter (greater than or equal to 5.0 ng per milliliter) in the elimination phase; and who also have a life-threatening arrhythmia, hemodynamic instability, hyperkalemia, or rapidly progressive toxicity. Digoxin 243-250 FA complementation group B Homo sapiens 31-34 1594015-14 1992 Adolescents, who are more sensitive to the toxic effects of digoxin than younger children, may require treatment with Fab after ingesting lower doses. Digoxin 60-67 FA complementation group B Homo sapiens 118-121 1579534-4 1992 If indicated, immunotherapy with digoxin immune Fab (Digibind) is a valuable and effective tool. Digoxin 33-40 FA complementation group B Homo sapiens 48-51 1588675-0 1992 Influence of assay methods on serum concentrations of digoxin during FAB fragment treatment. Digoxin 54-61 FA complementation group B Homo sapiens 69-72 1588675-1 1992 The treatment of digoxin intoxication has been revolutionized by digoxin specific antibody fragments (Fab). Digoxin 17-24 FA complementation group B Homo sapiens 102-105 1588675-1 1992 The treatment of digoxin intoxication has been revolutionized by digoxin specific antibody fragments (Fab). Digoxin 65-72 FA complementation group B Homo sapiens 102-105 1588675-4 1992 To investigate this discrepancy we compared serum samples spiked with digoxin from 0-50 ng/mL in the presence of increasing concentrations of digoxin specific Fab-fragments. Digoxin 142-149 FA complementation group B Homo sapiens 159-162 1585401-0 1992 Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Digoxin 28-35 FA complementation group B Homo sapiens 109-112 1585401-0 1992 Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Digoxin 54-61 FA complementation group B Homo sapiens 109-112 1585401-1 1992 Digoxin fab antibody therapy is known to interfere with digoxin immunoassays causing spurious serum digoxin concentrations. Digoxin 56-63 FA complementation group B Homo sapiens 8-11 1585401-1 1992 Digoxin fab antibody therapy is known to interfere with digoxin immunoassays causing spurious serum digoxin concentrations. Digoxin 100-107 FA complementation group B Homo sapiens 8-11 1585401-10 1992 Based on these results, FPIA-UF should be the assay of choice for determining free serum digoxin concentrations during fab therapy. Digoxin 89-96 FA complementation group B Homo sapiens 119-122 1605899-6 1992 Consequently, the clinician may be faced with the decision to use antidotal therapy with digoxin-specific Fab fragments (d-Fab). Digoxin 89-96 FA complementation group B Homo sapiens 106-109 1605899-6 1992 Consequently, the clinician may be faced with the decision to use antidotal therapy with digoxin-specific Fab fragments (d-Fab). Digoxin 89-96 FA complementation group B Homo sapiens 123-126 1605899-8 1992 Additionally, the treatment of acute digoxin toxicity in children is reviewed, especially as pertains to the therapeutic use of d-Fab. Digoxin 37-44 FA complementation group B Homo sapiens 130-133 1547603-8 1992 Digoxin-specific Fab antibody fragments may be used for treating digitalis toxicity refractory to conventional measures with a treatment response in at least 90% of patients with advanced and potentially life-threatening digitalis toxicity. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 1546393-2 1992 The sample"s drug reacts with an excess of an antidigoxin Fab"-beta-galactosidase monoconjugate and then the free monoconjugate is removed by polyacrylamide digitoxigenin-coupled beads; the beta-galactosidase activity of the supernatant measured photometrically at 634 nm is directly proportional to the digoxin concentration in the sample. Digoxin 50-57 FA complementation group B Homo sapiens 58-61 1624074-0 1992 [The monitoring of plasma digoxin levels during acute digitalis poisoning treated with Fab anti-digoxin fragments]. Digoxin 26-33 FA complementation group B Homo sapiens 87-90 1624074-0 1992 [The monitoring of plasma digoxin levels during acute digitalis poisoning treated with Fab anti-digoxin fragments]. Digoxin 96-103 FA complementation group B Homo sapiens 87-90 1624074-1 1992 Life-threatening digitalis intoxication is treated using digoxin specific antibody fragments (Fab) that bind and inactivate the drug. Digoxin 57-64 FA complementation group B Homo sapiens 94-97 1624074-2 1992 The free digoxin serum concentration could be useful in the management of Fab-treated patients, but the standard methods of measurement can be clinically misleading because Fab anti-digoxin interferes with digitalis immunoassay measurements. Digoxin 9-16 FA complementation group B Homo sapiens 74-77 1624074-2 1992 The free digoxin serum concentration could be useful in the management of Fab-treated patients, but the standard methods of measurement can be clinically misleading because Fab anti-digoxin interferes with digitalis immunoassay measurements. Digoxin 182-189 FA complementation group B Homo sapiens 173-176 1624074-3 1992 A case involving Fab therapy of a digoxin overdosed patient, in which two laboratory methods gave very different results, is reported. Digoxin 34-41 FA complementation group B Homo sapiens 17-20 1746476-0 1991 Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. Digoxin 86-93 FA complementation group B Homo sapiens 57-60 1746476-2 1991 Digoxin immune Fab[ovine]-Fab fragments (Digibind) have been shown to reverse digitalis toxicity and substantially reduce the risk of death. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 1746476-2 1991 Digoxin immune Fab[ovine]-Fab fragments (Digibind) have been shown to reverse digitalis toxicity and substantially reduce the risk of death. Digoxin 0-7 FA complementation group B Homo sapiens 26-29 1804104-2 1991 We here report on the preparation of an immunoaffinity chromatographic system (high affinity digoxin-binding antibodies (Fab fragments) bound covalently to Sepharose) for the purification of endogenous digitalis like factor(s). Digoxin 93-100 FA complementation group B Homo sapiens 121-124 1773486-4 1991 The products were characterized by FAB mass spectroscopy and shown to be the mono- and di-biotinylated digoxin conjugates of the oxidized glycose moiety. Digoxin 103-110 FA complementation group B Homo sapiens 35-38 1815424-0 1991 Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. Digoxin 41-48 FA complementation group B Homo sapiens 56-59 1815424-3 1991 The calculated elimination half-life of digoxin immune Fab was 25-73 hours. Digoxin 40-47 FA complementation group B Homo sapiens 55-58 1815424-5 1991 Free digoxin concentrations rebounded to a peak of 1-2.9 ng/mL 44-97 hours after the administration of digoxin immune Fab. Digoxin 5-12 FA complementation group B Homo sapiens 118-121 1815424-5 1991 Free digoxin concentrations rebounded to a peak of 1-2.9 ng/mL 44-97 hours after the administration of digoxin immune Fab. Digoxin 103-110 FA complementation group B Homo sapiens 118-121 1815424-7 1991 The total digoxin concentrations peaked at 14-33 times the pre-Fab digoxin concentrations 5-30 hours after digoxin immune Fab administration. Digoxin 10-17 FA complementation group B Homo sapiens 63-66 1815424-7 1991 The total digoxin concentrations peaked at 14-33 times the pre-Fab digoxin concentrations 5-30 hours after digoxin immune Fab administration. Digoxin 10-17 FA complementation group B Homo sapiens 122-125 1815424-8 1991 In comparing these data with data available from patients with normal renal function, the half-life of digoxin immune Fab and total digoxin was longer, the peak total digoxin concentration occurred later, the ratio of the peak total digoxin concentration to pre-Fab digoxin concentration was larger, and the rebound in free digoxin occurred later in patients with renal impairment. Digoxin 103-110 FA complementation group B Homo sapiens 118-121 1794217-0 1991 Retreatment with digoxin immune Fab. Digoxin 17-24 FA complementation group B Homo sapiens 32-35 1803787-0 1991 Monitoring serum digoxin concentrations during digoxin immune Fab therapy. Digoxin 17-24 FA complementation group B Homo sapiens 62-65 1803787-2 1991 Following administration of the antidote, digoxin immune antigen binding fragments (Fab), SDC monitoring is hampered by assay-related problems because of the presence of Fab in the serum. Digoxin 42-49 FA complementation group B Homo sapiens 84-87 1803787-2 1991 Following administration of the antidote, digoxin immune antigen binding fragments (Fab), SDC monitoring is hampered by assay-related problems because of the presence of Fab in the serum. Digoxin 42-49 FA complementation group B Homo sapiens 170-173 2244414-0 1990 Treatment of digitalis intoxication with emphasis on the clinical use of digoxin immune Fab. Digoxin 73-80 FA complementation group B Homo sapiens 88-91 1997017-0 1991 Experience with digoxin immune Fab (ovine) in patients with renal impairment. Digoxin 16-23 FA complementation group B Homo sapiens 31-34 1997017-1 1991 Digibind is a purified antigen binding fragment (Fab) of immunoglobulin G antibodies raised to bind digoxin. Digoxin 100-107 FA complementation group B Homo sapiens 49-52 1997017-3 1991 Thus it is expected that elimination of antidigoxin Fab fragments would be prolonged in patients with renal impairment; it remains unclear whether digoxin might be released with possible recurrence of toxicity. Digoxin 44-51 FA complementation group B Homo sapiens 52-55 1997018-8 1991 Hyperkalemia, when due to acute severe digoxin toxicity, is also an appropriate indication for digoxin-specific Fab fragment therapy. Digoxin 95-102 FA complementation group B Homo sapiens 112-115 1997019-10 1991 Because of the inherent difficulties in confirming the diagnosis of digitalis intoxication in some cases, digoxin-specific Fab antibodies may play a role as a diagnostic tool. Digoxin 106-113 FA complementation group B Homo sapiens 123-126 1997019-11 1991 Certainly, digoxin-specific Fab antibodies play a significant part in the treatment of digitalis intoxication. Digoxin 11-18 FA complementation group B Homo sapiens 28-31 1997019-12 1991 Fab antibodies have been successfully used to reverse the effects of digoxin, digitoxin, and oleander poisoning. Digoxin 69-76 FA complementation group B Homo sapiens 0-3 1997020-0 1991 Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. Digoxin 58-65 FA complementation group B Homo sapiens 73-76 1993775-0 1991 Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 1993775-1 1991 An observational surveillance study was conducted to monitor the safety and effectiveness of treatment with Digoxin Immune Fab (Ovine) (Digibind) in patients with digitalis intoxication. Digoxin 108-115 FA complementation group B Homo sapiens 123-126 1993775-2 1991 Before April 1986, a relatively limited number of patients received treatment with digoxin-specific Fab fragments through a multicenter clinical trial. Digoxin 83-90 FA complementation group B Homo sapiens 100-103 1985666-0 1991 Intraosseous digoxin immune FAB. Digoxin 13-20 FA complementation group B Homo sapiens 28-31 1748983-0 1991 Treatment of acute digoxin toxicosis with digoxin immune fab (Ovine). Digoxin 19-26 FA complementation group B Homo sapiens 57-60 1748983-0 1991 Treatment of acute digoxin toxicosis with digoxin immune fab (Ovine). Digoxin 42-49 FA complementation group B Homo sapiens 57-60 1949929-0 1991 Digoxin assay anomalies due to digoxin-specific Fab immunotherapy. Digoxin 0-7 FA complementation group B Homo sapiens 48-51 1949929-0 1991 Digoxin assay anomalies due to digoxin-specific Fab immunotherapy. Digoxin 31-38 FA complementation group B Homo sapiens 48-51 1949929-1 1991 We demonstrate that digoxin-specific Fab antibody fragments, used in the treatment of severe digitalis intoxication, cause a marked interference with both fluorescence excitation transfer immunoassays and radioimmunoassays for digoxin. Digoxin 20-27 FA complementation group B Homo sapiens 37-40 1949929-1 1991 We demonstrate that digoxin-specific Fab antibody fragments, used in the treatment of severe digitalis intoxication, cause a marked interference with both fluorescence excitation transfer immunoassays and radioimmunoassays for digoxin. Digoxin 227-234 FA complementation group B Homo sapiens 37-40 1854439-0 1991 Solution of a Fab (26-10)/digoxin complex by generalized molecular replacement. Digoxin 26-33 FA complementation group B Homo sapiens 14-17 1854439-1 1991 The structures of a Fab fragment of a monoclonal murine antidigoxin antibody (26-10) complexed with digoxin and of a mutant of the Fab itself have been solved by molecular replacement. Digoxin 60-67 FA complementation group B Homo sapiens 20-23 1854439-6 1991 After rigid-body refinement, the R factor was in the low forties at 8-2.5 and 8-2.7 A resolution for the Fab mutant and the Fab/digoxin complex, respectively. Digoxin 128-135 FA complementation group B Homo sapiens 124-127 1711637-1 1991 The effect of digoxin antibody fragments (Fab) on clearance of specifically bound digoxin from its specific receptor (Na, K-ATPase) was studied in human heart left ventricle (LV) and vastus lateralis skeletal muscle (SK) samples obtained postmortem. Digoxin 82-89 FA complementation group B Homo sapiens 42-45 1711637-4 1991 For SK, t1/2 was 5.4 h in buffer at 30 degrees C. Inhibition of rebinding of digoxin by addition of specific digoxin Fab (5 x 10(-7) M) or excess unlabeled digoxin (1 x 10(-4) M) to buffer at 30 degrees C increased net release rate for specifically bound digoxin 2.5- to 3.0-fold in heart and SK. Digoxin 109-116 FA complementation group B Homo sapiens 117-120 1711637-4 1991 For SK, t1/2 was 5.4 h in buffer at 30 degrees C. Inhibition of rebinding of digoxin by addition of specific digoxin Fab (5 x 10(-7) M) or excess unlabeled digoxin (1 x 10(-4) M) to buffer at 30 degrees C increased net release rate for specifically bound digoxin 2.5- to 3.0-fold in heart and SK. Digoxin 109-116 FA complementation group B Homo sapiens 117-120 1711637-4 1991 For SK, t1/2 was 5.4 h in buffer at 30 degrees C. Inhibition of rebinding of digoxin by addition of specific digoxin Fab (5 x 10(-7) M) or excess unlabeled digoxin (1 x 10(-4) M) to buffer at 30 degrees C increased net release rate for specifically bound digoxin 2.5- to 3.0-fold in heart and SK. Digoxin 109-116 FA complementation group B Homo sapiens 117-120 1711637-6 1991 Samples were subsequently washed in buffer containing 5 x 10(-7) M specific digoxin Fab for 16 h at 30 degrees C. This wash reduced occupancy of receptors by digoxin from 10 to 0.5% in LV and from 9 to 0.3% in SK, respectively. Digoxin 76-83 FA complementation group B Homo sapiens 84-87 1711637-6 1991 Samples were subsequently washed in buffer containing 5 x 10(-7) M specific digoxin Fab for 16 h at 30 degrees C. This wash reduced occupancy of receptors by digoxin from 10 to 0.5% in LV and from 9 to 0.3% in SK, respectively. Digoxin 158-165 FA complementation group B Homo sapiens 84-87 1997014-1 1991 Following the development of methods for eliciting and purifying digoxin-specific Fab fragments with high affinity and specificity for cardiac glycosides, clinical studies were undertaken as a multicenter, open-label trial to test safety and efficacy in patients with advanced and potentially life-threatening digitalis toxicity that failed to respond to conventional therapeutic measures. Digoxin 65-72 FA complementation group B Homo sapiens 82-85 1997014-8 1991 The data from this multicenter trial have been augmented by findings from an observational surveillance study conducted to monitor the safety and effectiveness of treatment with digoxin immune Fab (ovine) following commercial availability. Digoxin 178-185 FA complementation group B Homo sapiens 193-196 1997014-11 1991 In this clinical experience, digoxin-specific Fab was generally well tolerated and clinically effective in patients with potentially life-threatening digitalis toxicity. Digoxin 29-36 FA complementation group B Homo sapiens 46-49 1997016-2 1991 In this article the previous use of digoxin-specific antibody Fab fragments to treat digitalis overdose or intoxication in children is reviewed. Digoxin 36-43 FA complementation group B Homo sapiens 62-65 1805720-0 1991 Pharmacokinetics of total and free digoxin and Fab fragments in 5 intoxicated patients after administration of specific anti-digoxin Fab fragments. Digoxin 35-42 FA complementation group B Homo sapiens 133-136 1794007-15 1991 Immune Fab antibody is indicated for the management of digoxin toxicity, although patients dependent on the inotropic effect of digoxin may develop heart failure after digoxin Fab antibody administration. Digoxin 55-62 FA complementation group B Homo sapiens 7-10 1657202-3 1991 We here report that high affinity digoxin-binding antibodies (Fab fragments; Digibind, Burroughs Wellcome Co.) are capable of neutralizing the inhibitory activity on erythrocyte Rb uptake not only of digoxin but also of ouabain and of partially purified newborn EDLF. Digoxin 34-41 FA complementation group B Homo sapiens 62-65 1657202-3 1991 We here report that high affinity digoxin-binding antibodies (Fab fragments; Digibind, Burroughs Wellcome Co.) are capable of neutralizing the inhibitory activity on erythrocyte Rb uptake not only of digoxin but also of ouabain and of partially purified newborn EDLF. Digoxin 200-207 FA complementation group B Homo sapiens 62-65 2244414-4 1990 Digoxin immune Fab offers a safe, effective, and specific method of quickly reversing digitalis toxicity. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 2244414-6 1990 For severe, life-threatening toxicity, digoxin immune Fab is the treatment of choice. Digoxin 39-46 FA complementation group B Homo sapiens 54-57 2188752-0 1990 Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Digoxin 71-78 FA complementation group B Homo sapiens 88-91 2188752-2 1990 One hundred fifty patients with potentially life-threatening digitalis toxicity were treated with digoxin-specific antibody fragments (Fab) purified from immunoglobulin G produced in sheep. Digoxin 98-105 FA complementation group B Homo sapiens 135-138 2371148-0 1990 Use of digoxin Fab immune fragments in a seven-day-old infant. Digoxin 7-14 FA complementation group B Homo sapiens 15-18 2371148-1 1990 We report the use of digoxin immune Fab in a seven-day-old male neonate for treatment of digoxin poisoning. Digoxin 21-28 FA complementation group B Homo sapiens 36-39 2371148-1 1990 We report the use of digoxin immune Fab in a seven-day-old male neonate for treatment of digoxin poisoning. Digoxin 89-96 FA complementation group B Homo sapiens 36-39 2371148-5 1990 The patient received 40 mg of digoxin immune Fab fragments over one hour to bind a calculated maximum digoxin dose of 600 micrograms. Digoxin 30-37 FA complementation group B Homo sapiens 45-48 2371148-5 1990 The patient received 40 mg of digoxin immune Fab fragments over one hour to bind a calculated maximum digoxin dose of 600 micrograms. Digoxin 102-109 FA complementation group B Homo sapiens 45-48 2371148-8 1990 We believe that in massive and rapid electrolyte shifts in the neonate caused by digoxin immune Fab, glucose should be monitored closely. Digoxin 81-88 FA complementation group B Homo sapiens 96-99 2375888-0 1990 Specific anti-digoxin Fab fragments: an available antidote for proscillaridin and scilliroside poisoning? Digoxin 14-21 FA complementation group B Homo sapiens 22-25 2375888-1 1990 The purpose of this study was to evaluate the capacity of specific anti-digoxin Fab fragments to bind to and neutralize scilliroside and proscillaridin in acute poisoning. Digoxin 72-79 FA complementation group B Homo sapiens 80-83 2130529-4 1990 The direct immunofluorescence method with digoxin specific monoclonal antibody or Fab fragments and FITC or peroxidase conjugated antisera are useful for morphological examination of digoxin binding and localization in cardiac muscle cells. Digoxin 183-190 FA complementation group B Homo sapiens 82-85 2349615-1 1990 Following digoxin Fab antibody (FAB) administration in digitalis-toxic patients, total serum digoxin concentrations (SDCS) become elevated, but do not correlate with pharmacologic activity. Digoxin 10-17 FA complementation group B Homo sapiens 18-21 2349615-1 1990 Following digoxin Fab antibody (FAB) administration in digitalis-toxic patients, total serum digoxin concentrations (SDCS) become elevated, but do not correlate with pharmacologic activity. Digoxin 10-17 FA complementation group B Homo sapiens 32-35 2297154-0 1990 Near-fatal yew berry intoxication treated with external cardiac pacing and digoxin-specific FAB antibody fragments. Digoxin 75-82 FA complementation group B Homo sapiens 92-95 2297154-1 1990 The case of a 5-year-old girl who survived a near-fatal ingestion of yew plant leaves after treatment with CPR, transcutaneous pacing, and digoxin-specific FAB antibody fragments is presented. Digoxin 139-146 FA complementation group B Homo sapiens 156-159 2297154-5 1990 Two empiric injections of digoxin-specific FAB antibody fragments were administered, after which cardiac function and rhythm gradually improved. Digoxin 26-33 FA complementation group B Homo sapiens 43-46 2297154-9 1990 In addition, cross-reactivity between digoxin-specific FAB antibodies and the alkaloids in the yew plant may exist and may have therapeutic importance, although this mechanism was unlikely to have helped our patient. Digoxin 38-45 FA complementation group B Homo sapiens 55-58 2799159-7 1989 Because of persisting arrhythmias, hyperkalemia and a very high digitoxin level, purified Fab fragments of digoxin-specific antibodies (cross-reacting with digitoxin) were administered. Digoxin 107-114 FA complementation group B Homo sapiens 90-93 34424803-3 2022 However, a recent revision of internal Poisons Information Centre guidelines prompted a change of our recommendations, specifically instead of large boluses, to use titrating repeated low doses of digoxin antibodies(Digoxin-Fab) based on bedside assessment of cardiac toxicity. Digoxin 197-204 FA complementation group B Homo sapiens 224-227 34424803-14 2022 Median maximal change in HR post-Digoxin-Fab was 19 beats/min. Digoxin 33-40 FA complementation group B Homo sapiens 41-44 34424803-15 2022 The median potassium concentration decrease post-Digoxin-Fab was 0.3 mmol/L. Digoxin 49-56 FA complementation group B Homo sapiens 57-60 34424803-18 2022 Free digoxin concentrations dropped to almost zero after any dose of Digoxin-Fab. Digoxin 5-12 FA complementation group B Homo sapiens 77-80 2686397-1 1989 Digoxin immune Fab (ovine) (Digibind) is a preparation of Fab fragments of antidigoxin antibodies that is used as an antidote for severe digitalis toxicity. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 2686397-1 1989 Digoxin immune Fab (ovine) (Digibind) is a preparation of Fab fragments of antidigoxin antibodies that is used as an antidote for severe digitalis toxicity. Digoxin 0-7 FA complementation group B Homo sapiens 58-61 2595749-0 1989 Digoxin elimination in a functionally anephric patient after digoxin-specific Fab fragment therapy. Digoxin 0-7 FA complementation group B Homo sapiens 78-81 2595749-0 1989 Digoxin elimination in a functionally anephric patient after digoxin-specific Fab fragment therapy. Digoxin 61-68 FA complementation group B Homo sapiens 78-81 2595749-1 1989 The elimination of total digoxin after digoxin-specific Fab fragment therapy in a patient in end-stage renal disease is described. Digoxin 25-32 FA complementation group B Homo sapiens 56-59 2595749-1 1989 The elimination of total digoxin after digoxin-specific Fab fragment therapy in a patient in end-stage renal disease is described. Digoxin 39-46 FA complementation group B Homo sapiens 56-59 2814412-4 1989 Mainstays of management with favourable outcome were vomiting and gastric lavage, followed by administration of repeated doses of digoxin-specific Fab antibody fragments. Digoxin 130-137 FA complementation group B Homo sapiens 147-150 2592582-0 1989 Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose. Digoxin 33-40 FA complementation group B Homo sapiens 50-53 2592582-0 1989 Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose. Digoxin 93-100 FA complementation group B Homo sapiens 50-53 2592582-1 1989 The use of digoxin-specific Fab fragments (d-Fab) to treat life-threatening digitalis intoxication has been widely substantiated in adults. Digoxin 11-18 FA complementation group B Homo sapiens 28-31 2592582-1 1989 The use of digoxin-specific Fab fragments (d-Fab) to treat life-threatening digitalis intoxication has been widely substantiated in adults. Digoxin 11-18 FA complementation group B Homo sapiens 45-48 2592582-9 1989 Digoxin specific Fab fragments should be promptly administered to any infant or child with significant, life-threatening symptoms following acute digoxin intoxication. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 2592582-9 1989 Digoxin specific Fab fragments should be promptly administered to any infant or child with significant, life-threatening symptoms following acute digoxin intoxication. Digoxin 146-153 FA complementation group B Homo sapiens 17-20 2595117-0 1989 [Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody]. Digoxin 59-66 FA complementation group B Homo sapiens 76-79 2674405-1 1989 We describe a nonisotopic heterogeneous competitive immunoassay of digoxin in serum using either Fab fragments of a polyclonal antibody or a high-affinity monoclonal antibody. Digoxin 67-74 FA complementation group B Homo sapiens 97-100 2674405-2 1989 In the assay, digoxin competes with immobilized digoxin (digoxin:thyroglobulin conjugate) for binding to a biotinylated immunoreactant (Fab or monoclonal). Digoxin 14-21 FA complementation group B Homo sapiens 136-139 2674405-2 1989 In the assay, digoxin competes with immobilized digoxin (digoxin:thyroglobulin conjugate) for binding to a biotinylated immunoreactant (Fab or monoclonal). Digoxin 48-55 FA complementation group B Homo sapiens 136-139 2674405-2 1989 In the assay, digoxin competes with immobilized digoxin (digoxin:thyroglobulin conjugate) for binding to a biotinylated immunoreactant (Fab or monoclonal). Digoxin 48-55 FA complementation group B Homo sapiens 136-139 35330656-2 2021 Digoxin immune fab is a safe and effective antidote, but clinical trials have not been performed in this regard, and most of the evidence is based on prospective studies. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 35330656-10 2021 Digoxin immune fab was administered for 4.1% of patients, and an average of 6.2 +- 2.2 vials were used for them. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 2799159-10 1989 We confirm the effectiveness of digoxin-specific Fab antibody fragments in life-threatening digitoxin intoxication. Digoxin 32-39 FA complementation group B Homo sapiens 49-52 3776866-0 1986 Response of digoxin toxic atrial tachycardia to digoxin-specific Fab fragments. Digoxin 12-19 FA complementation group B Homo sapiens 65-68 2921838-1 1989 Severe digitalis intoxication today is preferentially treated by intravenous infusion of Fab fragments of digoxin antibodies (Digitalis Antidot BM). Digoxin 106-113 FA complementation group B Homo sapiens 89-92 2921838-4 1989 We observed a patient with life-threatening digitalis intoxication (serum digoxin, 3.7 ng/ml) and anuria, who was treated successfully by 160 mg Fab fragments i.v. Digoxin 74-81 FA complementation group B Homo sapiens 145-148 2644767-4 1989 The development of digoxin-specific Fab fragments has led to improvement in treatment of advanced and refractory digitalis toxicity and opens up the possibility of improvement in diagnosis of less clinically obvious cases of digitalis intoxication. Digoxin 19-26 FA complementation group B Homo sapiens 36-39 2910151-0 1989 Digoxin-immune Fab fragments. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 2708547-6 1989 It demonstrates the equimolar binding of the Fab-fragments for digoxin and shows that the elimination of the Fab-fragments can be established by a routine radioimmunoassay of digoxin, in an indirect way. Digoxin 63-70 FA complementation group B Homo sapiens 45-48 2708547-6 1989 It demonstrates the equimolar binding of the Fab-fragments for digoxin and shows that the elimination of the Fab-fragments can be established by a routine radioimmunoassay of digoxin, in an indirect way. Digoxin 175-182 FA complementation group B Homo sapiens 109-112 3382077-0 1988 Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Digoxin 35-42 FA complementation group B Homo sapiens 52-55 3382077-3 1988 The patient was treated empirically with a single dose of five vials (200 mg) of digoxin-specific Fab antibody fragments (Digibind). Digoxin 81-88 FA complementation group B Homo sapiens 98-101 2892273-0 1987 Fab fragments in the treatment of digoxin overdose: pediatric considerations. Digoxin 34-41 FA complementation group B Homo sapiens 0-3 2892273-6 1987 Fab fragments of digoxin-specific antibodies have been successfully used to treat refractory digoxin toxicity. Digoxin 17-24 FA complementation group B Homo sapiens 0-3 2892273-6 1987 Fab fragments of digoxin-specific antibodies have been successfully used to treat refractory digoxin toxicity. Digoxin 93-100 FA complementation group B Homo sapiens 0-3 3041099-5 1987 It is concluded that digoxin-specific Fab are capable of completely removing digoxin from its binding sites, the maximal rate of removal of digitalis glycosides from the (Na+ + K+)-ATPase is limited by the dissociation rate constant, and there is a close correlation between the degree of binding of digitalis glycosides to the (Na+ + K+)-ATPase and the increase in force of contraction. Digoxin 21-28 FA complementation group B Homo sapiens 38-41 3041099-5 1987 It is concluded that digoxin-specific Fab are capable of completely removing digoxin from its binding sites, the maximal rate of removal of digitalis glycosides from the (Na+ + K+)-ATPase is limited by the dissociation rate constant, and there is a close correlation between the degree of binding of digitalis glycosides to the (Na+ + K+)-ATPase and the increase in force of contraction. Digoxin 77-84 FA complementation group B Homo sapiens 38-41 18750248-0 1987 Emergency medicine: digoxin-specific fab fragments. Digoxin 20-27 FA complementation group B Homo sapiens 37-40 3568343-0 1987 Immunological reversal of digitalis toxicity by Fab fragments of digoxin-specific antibodies. Digoxin 65-72 FA complementation group B Homo sapiens 48-51 2520729-3 1989 The direct immunofluorescence staining technique with digoxin specific monoclonal antibody or Fab fragments and FITC or Texas-Red conjugated antisera are useful for morphological demonstration of digoxin binding and localization in cardiac cells. Digoxin 196-203 FA complementation group B Homo sapiens 94-97 3269336-0 1988 Digoxin immune Fab ovine. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 3415742-5 1988 A review of the pharmacology and indications for use of digoxin-immune Fab fragments is also presented. Digoxin 56-63 FA complementation group B Homo sapiens 71-74 3056845-8 1988 Other advances in clinical toxicology include the introduction of the opiate antagonist naloxone, Fab antibody fragments for life-threatening digoxin overdosage and proven treatment for paracetamol poisoning. Digoxin 142-149 FA complementation group B Homo sapiens 98-101 3663292-0 1987 Fatal digoxin poisoning: an unsuccessful resuscitation with use of digoxin-immune Fab. Digoxin 6-13 FA complementation group B Homo sapiens 82-85 3663292-0 1987 Fatal digoxin poisoning: an unsuccessful resuscitation with use of digoxin-immune Fab. Digoxin 67-74 FA complementation group B Homo sapiens 82-85 3663292-3 1987 The infant died despite intensive resuscitative efforts, including the use of digoxin-specific Fab antibodies. Digoxin 78-85 FA complementation group B Homo sapiens 95-98 3123849-0 1987 Digoxin immune Fab. Digoxin 0-7 FA complementation group B Homo sapiens 15-18 3041099-0 1987 Reversal of toxic and non-toxic effects of digoxin by digoxin-specific Fab fragments in isolated human ventricular myocardium. Digoxin 43-50 FA complementation group B Homo sapiens 71-74 3041099-0 1987 Reversal of toxic and non-toxic effects of digoxin by digoxin-specific Fab fragments in isolated human ventricular myocardium. Digoxin 54-61 FA complementation group B Homo sapiens 71-74 3041099-1 1987 The time course of the reversal of toxic and nontoxic effects of digoxin by digoxin-specific antibody fragments (Fab) was measured in isolated human ventricular myocardium. Digoxin 65-72 FA complementation group B Homo sapiens 113-116 3041099-1 1987 The time course of the reversal of toxic and nontoxic effects of digoxin by digoxin-specific antibody fragments (Fab) was measured in isolated human ventricular myocardium. Digoxin 76-83 FA complementation group B Homo sapiens 113-116 3041099-3 1987 After addition of a 1.5-fold higher molar concentration of digoxin-specific Fab, signs of toxicity disappeared within 30 min and digoxin-induced force of contraction decayed with a monoexponential time course with a half-life of 52 min. Digoxin 59-66 FA complementation group B Homo sapiens 76-79 3041099-3 1987 After addition of a 1.5-fold higher molar concentration of digoxin-specific Fab, signs of toxicity disappeared within 30 min and digoxin-induced force of contraction decayed with a monoexponential time course with a half-life of 52 min. Digoxin 129-136 FA complementation group B Homo sapiens 76-79 3610566-0 1987 Treatment of digoxin toxicity with digoxin immune Fab. Digoxin 13-20 FA complementation group B Homo sapiens 50-53 3610566-0 1987 Treatment of digoxin toxicity with digoxin immune Fab. Digoxin 35-42 FA complementation group B Homo sapiens 50-53 2848937-1 1987 Metabolic effects of digitalis intoxication in a premature infant: treatment with digoxin-specific Fab fragments. Digoxin 82-89 FA complementation group B Homo sapiens 99-102 3776866-0 1986 Response of digoxin toxic atrial tachycardia to digoxin-specific Fab fragments. Digoxin 48-55 FA complementation group B Homo sapiens 65-68 3526993-3 1986 Digoxin-specific Fab fragments rapidly reverse digitalis toxicity in animals and man. Digoxin 0-7 FA complementation group B Homo sapiens 17-20 3526993-5 1986 Anti-digoxin Fab fragments have been approved by the Food and Drug Administration for the treatment of digitalis intoxication. Digoxin 5-12 FA complementation group B Homo sapiens 13-16 2429280-0 1986 Electrocardiographic response of digoxin-toxic fascicular tachycardia to Fab fragments: implications for tachycardia mechanism. Digoxin 33-40 FA complementation group B Homo sapiens 73-76 2429280-1 1986 The electrocardiographic response of digoxin-induced fascicular tachycardia to Fab fragments was evaluated in two patients. Digoxin 37-44 FA complementation group B Homo sapiens 79-82 2429280-5 1986 We conclude that Fab administration can promptly resolve fascicular tachycardias precipitated by digoxin toxicity and that the observed electrocardiographic phenomena strongly suggest triggered activity as the electrophysiologic mechanism of fascicular tachycardia in man. Digoxin 97-104 FA complementation group B Homo sapiens 17-20 3886748-1 1985 Sixty-three patients with life-threatening digitalis intoxication were treated with purified fragments of digoxin-specific antibodies (Fab) obtained from sheep. Digoxin 106-113 FA complementation group B Homo sapiens 135-138 3698816-0 1986 Use of digoxin-specific Fab fragments in the treatment of digitalis intoxication. Digoxin 7-14 FA complementation group B Homo sapiens 24-27 3774436-3 1986 We report one case of Digoxin intoxication in a child treated with Fab Fragments of Digoxin-Specific antibodies (Fabad), although there was no evidence of early life threatening complications. Digoxin 22-29 FA complementation group B Homo sapiens 67-70 3774436-3 1986 We report one case of Digoxin intoxication in a child treated with Fab Fragments of Digoxin-Specific antibodies (Fabad), although there was no evidence of early life threatening complications. Digoxin 84-91 FA complementation group B Homo sapiens 67-70 3739069-0 1986 Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning. Digoxin 7-14 FA complementation group B Homo sapiens 44-47 3739069-0 1986 Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning. Digoxin 70-77 FA complementation group B Homo sapiens 44-47 3758140-0 1986 Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Digoxin 33-40 FA complementation group B Homo sapiens 16-19 3758140-1 1986 17 patients with severe digoxin intoxication were successfully treated with 320 to 480 mg Fab fragments of digoxin-specific IgG from sheep. Digoxin 24-31 FA complementation group B Homo sapiens 90-93 3758140-1 1986 17 patients with severe digoxin intoxication were successfully treated with 320 to 480 mg Fab fragments of digoxin-specific IgG from sheep. Digoxin 107-114 FA complementation group B Homo sapiens 90-93 3758140-2 1986 The infusion period ranged between 0.5 and 7 h. Serum and urine concentrations of digoxin bound to Fab fragments, and in 11 cases unbound Fab fragments in serum, were determined during and after the infusion. Digoxin 82-89 FA complementation group B Homo sapiens 99-102 3537615-7 1986 Two immunotherapeutic modalities, digoxin-specific antibody fragments (Fab) and snake antivenin, have been available for the clinician"s armamentarium for years. Digoxin 34-41 FA complementation group B Homo sapiens 71-74 2999197-7 1985 Recent studies have shown that monoclonal digoxin-specific antibodies and Fab fragments obtained by somatic cell fusion are effective in reversing advanced and otherwise lethal digoxin intoxication. Digoxin 177-184 FA complementation group B Homo sapiens 74-77 4056378-0 1985 Purified digoxin specific Fab fragments. Digoxin 9-16 FA complementation group B Homo sapiens 26-29 3986060-0 1985 Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Digoxin 22-29 FA complementation group B Homo sapiens 39-42 3986060-0 1985 Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Digoxin 57-64 FA complementation group B Homo sapiens 39-42 3986060-3 1985 Because of persistent hyperkalaemia he was also treated with Fab fragments of digoxin specific antibody, which bound most of the ingested digoxin. Digoxin 78-85 FA complementation group B Homo sapiens 61-64 3986060-3 1985 Because of persistent hyperkalaemia he was also treated with Fab fragments of digoxin specific antibody, which bound most of the ingested digoxin. Digoxin 138-145 FA complementation group B Homo sapiens 61-64 3886748-3 1985 The dosage of digoxin-specific Fab was calculated to be equimolar to the amount of cardiac glycoside in the patient"s body. Digoxin 14-21 FA complementation group B Homo sapiens 31-34 3886748-8 1985 Potentially life-threatening digitalis intoxication can be rapidly and safely reversed by treatment with purified digoxin-specific Fab fragments. Digoxin 114-121 FA complementation group B Homo sapiens 131-134 3970406-0 1985 Use of fab fragments of digoxin-specific antibodies in the therapy of massive digoxin poisoning. Digoxin 24-31 FA complementation group B Homo sapiens 7-10 3970406-0 1985 Use of fab fragments of digoxin-specific antibodies in the therapy of massive digoxin poisoning. Digoxin 78-85 FA complementation group B Homo sapiens 7-10 3970406-2 1985 The arrhythmias ceased following administration of digoxin-specific Fab fragments. Digoxin 51-58 FA complementation group B Homo sapiens 68-71 2859831-5 1985 Digitalis toxicity resistant to conventional measures may now be treated with digoxin-specific Fab fragments. Digoxin 78-85 FA complementation group B Homo sapiens 95-98 4059073-0 1985 Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies. Digoxin 0-7 FA complementation group B Homo sapiens 55-58 4057323-0 1985 Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. Digoxin 0-7 FA complementation group B Homo sapiens 27-30 4057323-1 1985 34 patients aged between 2 and 80 years were treated with digoxin specific antibody (Fab) fragments for severe digitalis poisoning. Digoxin 58-65 FA complementation group B Homo sapiens 85-88 4059073-0 1985 Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies. Digoxin 72-79 FA complementation group B Homo sapiens 55-58 4059073-1 1985 The first use of Fab fragments to treat digoxin toxicity in a premature infant with renal failure, 18 h after the onset of severe arrhythmias, is reported with dramatic results. Digoxin 40-47 FA complementation group B Homo sapiens 17-20 6468431-0 1984 Severe digoxin intoxication in a child treated by infusion of digoxin-specific Fab-antibody-fragments. Digoxin 7-14 FA complementation group B Homo sapiens 79-82 6468431-0 1984 Severe digoxin intoxication in a child treated by infusion of digoxin-specific Fab-antibody-fragments. Digoxin 62-69 FA complementation group B Homo sapiens 79-82 6468431-4 1984 As the serum digoxin level reached 21.7 ng/ml digoxin-specific Fab-antibody-fragments were used to bind free serum digoxin. Digoxin 13-20 FA complementation group B Homo sapiens 63-66 6468431-4 1984 As the serum digoxin level reached 21.7 ng/ml digoxin-specific Fab-antibody-fragments were used to bind free serum digoxin. Digoxin 46-53 FA complementation group B Homo sapiens 63-66 6468431-4 1984 As the serum digoxin level reached 21.7 ng/ml digoxin-specific Fab-antibody-fragments were used to bind free serum digoxin. Digoxin 46-53 FA complementation group B Homo sapiens 63-66 6333127-0 1984 Treatment of severe digitoxin intoxication by digoxin-specific Fab antibody fragments. Digoxin 46-53 FA complementation group B Homo sapiens 63-66 6626440-0 1983 Plasma digoxin: assay anomalies in Fab-treated patients. Digoxin 7-14 FA complementation group B Homo sapiens 35-38 6884234-0 1983 [Antidigoxin Fab-fragments in suicidal digoxin poisoning. Digoxin 5-12 FA complementation group B Homo sapiens 13-16 6884234-4 1983 Sheep Fab fragments of digoxin-specific antibodies were administered i. v. at a dose of 480 mg. Serum free-digoxin concentration fell within half an hour to 0, with simultaneous rise of total digoxin from 13 micrograms/l to a maximum of 176 micrograms/l after 2 hours. Digoxin 23-30 FA complementation group B Homo sapiens 6-9 6866048-0 1983 Treatment of digitalis intoxication with digoxin-specific Fab antibody fragments. Digoxin 41-48 FA complementation group B Homo sapiens 58-61 5289875-5 1971 At near-stoichiometric concentrations, either purified antibody to digoxin, or its papain-digested product (Fab-Fc), reversed digoxin-induced: (a) inhibition of (86)Rb transport in human erythrocytes, (b) increase in developed tension in isolated guinea-pig atrial strips, and (c) ventricular tachycardia in intact dogs, and also corrected digoxin-induced automaticity in isolated guineapig atrial strips. Digoxin 126-133 FA complementation group B Homo sapiens 108-111 6842605-0 1983 Crystallization of the Fab fragment of a monoclonal anti-digoxin antibody and its complex with digoxin. Digoxin 57-64 FA complementation group B Homo sapiens 23-26 6842605-0 1983 Crystallization of the Fab fragment of a monoclonal anti-digoxin antibody and its complex with digoxin. Digoxin 95-102 FA complementation group B Homo sapiens 23-26 6848964-0 1983 Fab fragments in treatment of digoxin ingestion. Digoxin 30-37 FA complementation group B Homo sapiens 0-3 6752715-0 1982 Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. Digoxin 58-65 FA complementation group B Homo sapiens 75-78 6752715-1 1982 Purified Fab fragments of digoxin-specific antibodies obtained from sheep were used to treat 26 patients with advanced, life-threatening digoxin (23 cases) or digitoxin (3 cases) toxicity. Digoxin 26-33 FA complementation group B Homo sapiens 9-12 6752715-1 1982 Purified Fab fragments of digoxin-specific antibodies obtained from sheep were used to treat 26 patients with advanced, life-threatening digoxin (23 cases) or digitoxin (3 cases) toxicity. Digoxin 137-144 FA complementation group B Homo sapiens 9-12 6752715-8 1982 We conclude that the use of purified digoxin-specific Fab fragments is a safe and effective means to reverse advanced, life-threatening digitalis intoxication. Digoxin 37-44 FA complementation group B Homo sapiens 54-57 7145680-1 1982 Treatment with Fab fragments of anti-digoxin antibodies]. Digoxin 37-44 FA complementation group B Homo sapiens 15-18 7110822-0 1982 Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child. Digoxin 17-24 FA complementation group B Homo sapiens 0-3 7110822-0 1982 Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child. Digoxin 97-104 FA complementation group B Homo sapiens 0-3 7110822-3 1982 After two hours the boy was given digoxin-specific Fab fragments of antibody in sufficient quantity to bind his estimated dose of 10 mg. By completion of the treatment minutes later, normal rhythm and circulation were restored. Digoxin 34-41 FA complementation group B Homo sapiens 51-54 7110822-8 1982 Administration of purified Fab fragments of digoxin-specific antibodies can be life saving in children with digitalis poisoning, and prolonged cardiopulmonary resuscitation in children is justified when the cause of cardiac arrest is potentially reversible. Digoxin 44-51 FA complementation group B Homo sapiens 27-30 7110823-0 1982 Massive digoxin poisoning treated with Fab fragments of digoxin-specific antibodies. Digoxin 8-15 FA complementation group B Homo sapiens 39-42 7110823-0 1982 Massive digoxin poisoning treated with Fab fragments of digoxin-specific antibodies. Digoxin 56-63 FA complementation group B Homo sapiens 39-42 368816-6 1979 The use of antigen-binding (Fab) fragments of digoxin-specific antibodies offer the advantage of rapid renal elimination of bound and inactivated digoxin. Digoxin 46-53 FA complementation group B Homo sapiens 28-31 368816-6 1979 The use of antigen-binding (Fab) fragments of digoxin-specific antibodies offer the advantage of rapid renal elimination of bound and inactivated digoxin. Digoxin 146-153 FA complementation group B Homo sapiens 28-31 368816-7 1979 So far, due to potential immune reactions, the clinical use of purified digoxin-specific antibodies of Fab fragments is restricted to life-threatening accidental or suicidal digoxin or digitoxin poisoning. Digoxin 72-79 FA complementation group B Homo sapiens 103-106 368816-7 1979 So far, due to potential immune reactions, the clinical use of purified digoxin-specific antibodies of Fab fragments is restricted to life-threatening accidental or suicidal digoxin or digitoxin poisoning. Digoxin 174-181 FA complementation group B Homo sapiens 103-106 299860-1 1977 Intact sheep antidigoxin antibodies and their Fab fragments have both been found to exert profound effects on digoxin pharmacokinetics in [3H] digoxin-treated dogs. Digoxin 138-150 FA complementation group B Homo sapiens 46-49 299860-4 1977 In contrast, urinary excretion of digoxin continues in Fab-treated dogs, with significant quantities of digoxin being excreted promptly in the urine in complex with Fab fragments. Digoxin 34-41 FA complementation group B Homo sapiens 55-58 299860-5 1977 These differences in urinary excretion, together with the probable decreased immunogenicity of sheep antidigoxin Fab fragments, suggest that such fragments possess potential advantages over intact antibody molecules for use in the therapy of life-threatening digoxin intoxication in man. Digoxin 105-112 FA complementation group B Homo sapiens 113-116 7162976-0 1982 [Digitoxin poisoning: reversing ventricular fibrillation with Fab fragments of anti-digoxin antibody]. Digoxin 84-91 FA complementation group B Homo sapiens 62-65 7162976-1 1982 Purified Fab fragments of ovine anti-digoxin antibodies (Wellcome Foundation) were used to treat a patient who attempted suicide by absorbing 10 mg of digitoxin (serum concentration 265 micrograms/l). Digoxin 37-44 FA complementation group B Homo sapiens 9-12 943040-0 1976 Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. Digoxin 21-28 FA complementation group B Homo sapiens 47-50 943040-0 1976 Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. Digoxin 64-71 FA complementation group B Homo sapiens 47-50 943040-1 1976 Purified Fab fragments of ovine digoxin-specific antibodies reversed severe digoxin intoxication in a patient who had taken 22.5 mg of the drug with suicidal intent. Digoxin 32-39 FA complementation group B Homo sapiens 9-12 943040-1 1976 Purified Fab fragments of ovine digoxin-specific antibodies reversed severe digoxin intoxication in a patient who had taken 22.5 mg of the drug with suicidal intent. Digoxin 76-83 FA complementation group B Homo sapiens 9-12 943040-6 1976 Renal excretion of digoxin bound to Fab was documented. Digoxin 19-26 FA complementation group B Homo sapiens 36-39 943040-8 1976 Thus, purified digoxin-specific Fab fragments are capable of rapid reversal of advanced digoxin toxicity. Digoxin 15-22 FA complementation group B Homo sapiens 32-35 943040-8 1976 Thus, purified digoxin-specific Fab fragments are capable of rapid reversal of advanced digoxin toxicity. Digoxin 88-95 FA complementation group B Homo sapiens 32-35 5289875-5 1971 At near-stoichiometric concentrations, either purified antibody to digoxin, or its papain-digested product (Fab-Fc), reversed digoxin-induced: (a) inhibition of (86)Rb transport in human erythrocytes, (b) increase in developed tension in isolated guinea-pig atrial strips, and (c) ventricular tachycardia in intact dogs, and also corrected digoxin-induced automaticity in isolated guineapig atrial strips. Digoxin 126-133 FA complementation group B Homo sapiens 108-111 33476509-1 2020 A review of the evidence behind the DigiFab dosing calculator, which provides dosing for digoxin immune Fab in patients with confirmed digoxin poisoning or overdose. Digoxin 90-97 FA complementation group B Homo sapiens 40-43 33721285-0 2021 Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986-2019. Digoxin 38-45 FA complementation group B Homo sapiens 53-56 33569535-8 2021 Initially, treatment was with digoxin-specific antibody (FAB) and fluid resuscitation. Digoxin 30-37 FA complementation group B Homo sapiens 57-60 32770621-3 2020 Cessation of the drug, appropriate electrolyte and rhythm control and digoxin-Fab antibody are the mainstay for toxicity treatment in these patients. Digoxin 70-77 FA complementation group B Homo sapiens 78-81 32770621-7 2020 Without the treatment using digoxin-specific Fab antibodies, the patient"s digoxin level was decreased successfully with continuous venovenous hemodialysis. Digoxin 28-35 FA complementation group B Homo sapiens 45-48 32770621-7 2020 Without the treatment using digoxin-specific Fab antibodies, the patient"s digoxin level was decreased successfully with continuous venovenous hemodialysis. Digoxin 75-82 FA complementation group B Homo sapiens 45-48 32387148-4 2020 Despite the administration of a total of nine vials of digoxin-specific Fab the patient could not be resuscitated. Digoxin 55-62 FA complementation group B Homo sapiens 72-75 27118413-1 2016 CONTEXT: We hypothesized that in chronic digoxin toxicity, anti-digoxin antibodies (Fab) would be efficacious in binding digoxin, but this may not translate into improved clinical outcomes. Digoxin 41-48 FA complementation group B Homo sapiens 84-87 30306803-1 2019 CONTEXT: Recommended doses of digoxin-specific antibody fragments (digoxin-Fab) for treatment of acute digoxin poisoning are pharmacokinetically unsubstantiated and theoretically excessive. Digoxin 30-37 FA complementation group B Homo sapiens 75-78 30306803-1 2019 CONTEXT: Recommended doses of digoxin-specific antibody fragments (digoxin-Fab) for treatment of acute digoxin poisoning are pharmacokinetically unsubstantiated and theoretically excessive. Digoxin 67-74 FA complementation group B Homo sapiens 75-78 30306803-9 2019 Simulation capacity provides realistic, continuous data which has the potential to substantiate alternative, less expensive, and safer digoxin-Fab dosing strategies for the treatment of acute digoxin toxicity. Digoxin 135-142 FA complementation group B Homo sapiens 143-146 31951334-14 2019 Two premature neonates were treated with digoxin-specific antibody Fab fragments (DigiFab ) and hypokalemia developed in both of them. Digoxin 41-48 FA complementation group B Homo sapiens 67-70 27118413-19 2016 CONCLUSIONS: One to two vials of anti-digoxin Fab initially bound all free digoxin confirming Fab efficacy. Digoxin 38-45 FA complementation group B Homo sapiens 46-49 27118413-19 2016 CONCLUSIONS: One to two vials of anti-digoxin Fab initially bound all free digoxin confirming Fab efficacy. Digoxin 38-45 FA complementation group B Homo sapiens 94-97 27118413-19 2016 CONCLUSIONS: One to two vials of anti-digoxin Fab initially bound all free digoxin confirming Fab efficacy. Digoxin 75-82 FA complementation group B Homo sapiens 46-49 27118413-19 2016 CONCLUSIONS: One to two vials of anti-digoxin Fab initially bound all free digoxin confirming Fab efficacy. Digoxin 75-82 FA complementation group B Homo sapiens 94-97 29941374-9 2018 Anti-digoxin immune FAB may be ineffective in a large pong-pong seed ingestion. Digoxin 5-12 FA complementation group B Homo sapiens 20-23 27118413-1 2016 CONTEXT: We hypothesized that in chronic digoxin toxicity, anti-digoxin antibodies (Fab) would be efficacious in binding digoxin, but this may not translate into improved clinical outcomes. Digoxin 64-71 FA complementation group B Homo sapiens 84-87 27118413-1 2016 CONTEXT: We hypothesized that in chronic digoxin toxicity, anti-digoxin antibodies (Fab) would be efficacious in binding digoxin, but this may not translate into improved clinical outcomes. Digoxin 64-71 FA complementation group B Homo sapiens 84-87 27118413-2 2016 OBJECTIVE: This study aims to investigate changes in free digoxin concentrations and clinical effects on heart rate and potassium concentrations in chronic digoxin poisoning when anti-digoxin Fab are given. Digoxin 58-65 FA complementation group B Homo sapiens 192-195 27118413-2 2016 OBJECTIVE: This study aims to investigate changes in free digoxin concentrations and clinical effects on heart rate and potassium concentrations in chronic digoxin poisoning when anti-digoxin Fab are given. Digoxin 156-163 FA complementation group B Homo sapiens 192-195 27118413-2 2016 OBJECTIVE: This study aims to investigate changes in free digoxin concentrations and clinical effects on heart rate and potassium concentrations in chronic digoxin poisoning when anti-digoxin Fab are given. Digoxin 156-163 FA complementation group B Homo sapiens 192-195 27118413-4 2016 Patients were recruited if they have been treated with anti-digoxin Fab for chronic digoxin poisoning. Digoxin 60-67 FA complementation group B Homo sapiens 68-71 27118413-4 2016 Patients were recruited if they have been treated with anti-digoxin Fab for chronic digoxin poisoning. Digoxin 84-91 FA complementation group B Homo sapiens 68-71 27118413-13 2016 Median change in HR was 8 beats/min post-Fab with no effect on blood pressure; they were 4, 10 and 17 beats/min for the 1, 2 and >=3 vials of anti-digoxin Fab groups respectively. Digoxin 150-157 FA complementation group B Homo sapiens 158-161 27118413-17 2016 Digoxin concentration reduced from 3.8 to 0 nmol/L post-Fab. Digoxin 0-7 FA complementation group B Homo sapiens 56-59 26929880-5 2016 The discontinuation of digoxin and the administration of digoxin specific immunoglobulin fragments (Fab) reversed those changes. Digoxin 57-64 FA complementation group B Homo sapiens 100-103 26505271-10 2016 Recent data suggest that existing methods for calculating the dose of anti-digoxin Fab in digoxin poisoning overstate the dose required, and that its efficacy may be minimal in patients with chronic digoxin poisoning. Digoxin 75-82 FA complementation group B Homo sapiens 83-86 26505271-10 2016 Recent data suggest that existing methods for calculating the dose of anti-digoxin Fab in digoxin poisoning overstate the dose required, and that its efficacy may be minimal in patients with chronic digoxin poisoning. Digoxin 90-97 FA complementation group B Homo sapiens 83-86 26505271-10 2016 Recent data suggest that existing methods for calculating the dose of anti-digoxin Fab in digoxin poisoning overstate the dose required, and that its efficacy may be minimal in patients with chronic digoxin poisoning. Digoxin 90-97 FA complementation group B Homo sapiens 83-86 25221680-8 2014 The patient developed a bidirectional tachycardia and the Poison Control Center of the hospital provided digoxin immune fab. Digoxin 105-112 FA complementation group B Homo sapiens 120-123 25379735-2 2016 Fortunately, digoxin-specific Fab fragments are commercially available as an antidote. Digoxin 13-20 FA complementation group B Homo sapiens 30-33 24023070-0 2014 Recurrence of digoxin toxicity following treatment with digoxin immune fab in a patient with renal impairment. Digoxin 14-21 FA complementation group B Homo sapiens 71-74 24023070-0 2014 Recurrence of digoxin toxicity following treatment with digoxin immune fab in a patient with renal impairment. Digoxin 56-63 FA complementation group B Homo sapiens 71-74 24023070-1 2014 In patients with chronic digoxin toxicity, especially in the presence of renal impairment, a prolonged duration of continuous monitoring is required with consideration given to further doses of immune fab if necessary for re-emergence of toxicity. Digoxin 25-32 FA complementation group B Homo sapiens 201-204 25379735-0 2016 Assessment of Digoxin-Specific Fab Fragment Dosages in Digoxin Poisoning. Digoxin 14-21 FA complementation group B Homo sapiens 31-34 25379735-0 2016 Assessment of Digoxin-Specific Fab Fragment Dosages in Digoxin Poisoning. Digoxin 55-62 FA complementation group B Homo sapiens 31-34 25379735-4 2016 There is a standardized formula to calculate appropriate Fab fragment dosage based on the serum digoxin concentration. Digoxin 96-103 FA complementation group B Homo sapiens 57-60 25379735-7 2016 We performed this study to assess the amounts of digoxin-specific Fab fragments administered in the treatment of digoxin poisonings recorded in a poison control system database from January 1, 2000, to December 31, 2009, in which digoxin serum concentrations were available. Digoxin 49-56 FA complementation group B Homo sapiens 66-69 25379735-7 2016 We performed this study to assess the amounts of digoxin-specific Fab fragments administered in the treatment of digoxin poisonings recorded in a poison control system database from January 1, 2000, to December 31, 2009, in which digoxin serum concentrations were available. Digoxin 113-120 FA complementation group B Homo sapiens 66-69 25379735-7 2016 We performed this study to assess the amounts of digoxin-specific Fab fragments administered in the treatment of digoxin poisonings recorded in a poison control system database from January 1, 2000, to December 31, 2009, in which digoxin serum concentrations were available. Digoxin 113-120 FA complementation group B Homo sapiens 66-69 25379735-11 2016 Our data suggests that clinician education on digoxin poisoning and the use of the standardized formula to calculate the Fab dose may decrease over utilization and decrease costs associated with the administration of digoxin-specific Fab fragments in the treatment of digoxin poisonings. Digoxin 217-224 FA complementation group B Homo sapiens 121-124 25379735-11 2016 Our data suggests that clinician education on digoxin poisoning and the use of the standardized formula to calculate the Fab dose may decrease over utilization and decrease costs associated with the administration of digoxin-specific Fab fragments in the treatment of digoxin poisonings. Digoxin 217-224 FA complementation group B Homo sapiens 234-237 25379735-11 2016 Our data suggests that clinician education on digoxin poisoning and the use of the standardized formula to calculate the Fab dose may decrease over utilization and decrease costs associated with the administration of digoxin-specific Fab fragments in the treatment of digoxin poisonings. Digoxin 217-224 FA complementation group B Homo sapiens 121-124 25379735-11 2016 Our data suggests that clinician education on digoxin poisoning and the use of the standardized formula to calculate the Fab dose may decrease over utilization and decrease costs associated with the administration of digoxin-specific Fab fragments in the treatment of digoxin poisonings. Digoxin 217-224 FA complementation group B Homo sapiens 234-237 25089630-1 2014 CONTEXT: Digoxin-specific antibody fragments (digoxin-Fab) are widely regarded as a safe and effective treatment for the management of acute and chronic digoxin poisoning. Digoxin 9-16 FA complementation group B Homo sapiens 54-57 25089630-1 2014 CONTEXT: Digoxin-specific antibody fragments (digoxin-Fab) are widely regarded as a safe and effective treatment for the management of acute and chronic digoxin poisoning. Digoxin 46-53 FA complementation group B Homo sapiens 54-57 25089630-4 2014 METHODS: Pubmed, Embase, Medline and Cochrane were searched from 1946 to May 2013 using the terms digoxin, digoxin-specific Fab, and digoxin antibody. Digoxin 107-114 FA complementation group B Homo sapiens 124-127 25089630-4 2014 METHODS: Pubmed, Embase, Medline and Cochrane were searched from 1946 to May 2013 using the terms digoxin, digoxin-specific Fab, and digoxin antibody. Digoxin 107-114 FA complementation group B Homo sapiens 124-127 25089630-9 2014 A 40-mg vial of digoxin-Fab (DigiFab) binds 0.5 mg digoxin. Digoxin 16-23 FA complementation group B Homo sapiens 24-27 25089630-11 2014 The half-lives of both digoxin and digoxin-Fab are prolonged in renal failure to over 100 h. Efficacy and effectiveness of digoxin-Fab. Digoxin 23-30 FA complementation group B Homo sapiens 131-134 25089630-13 2014 Ten case series with a total of 2,080 patients have reported on the use of digoxin-Fab in digoxin poisoning. Digoxin 75-82 FA complementation group B Homo sapiens 83-86 25089630-16 2014 Studies with pharmacokinetic data showed that free digoxin concentration fell to almost zero within a few minutes following the administration of digoxin-Fab. Digoxin 51-58 FA complementation group B Homo sapiens 154-157 25089630-17 2014 Digoxin-Fab was used more frequently in acute than chronic digoxin poisoning with a higher reported success rate when used in acute overdose. Digoxin 59-66 FA complementation group B Homo sapiens 8-11 25089630-27 2014 Digoxin load based on ingested dose will generally overestimate digoxin-Fab doses as bioavailability is 60-80%, and further reduced by vomiting and activated charcoal. Digoxin 0-7 FA complementation group B Homo sapiens 72-75 25089630-29 2014 Much smaller doses of digoxin-Fab can eliminate the digoxin in the central compartment (Vd 55 L). Digoxin 22-29 FA complementation group B Homo sapiens 30-33 25089630-37 2014 CONCLUSIONS: Digoxin-Fab is safe and indicated in all patients with life-threatening arrhythmias and an elevated digoxin concentration. Digoxin 113-120 FA complementation group B Homo sapiens 21-24 25221680-12 2014 Digoxin immune fab represents a safe, effective, and specific method for rapidly reversing digitalis cardiotoxicity and should be started as soon as the diagnosis is defined. Digoxin 0-7 FA complementation group B Homo sapiens 15-18